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ABSTRACT            
 
Of all cancers, colorectal cancer has the fourth highest incidence rate worldwide and it is estimated 
that colorectal cancer is responsible for the deaths of approximately 608,000 people each year. Due 
to improved detection and treatment protocols, mortality from this disease has decreased in recent 
years, with 5-year survival rates for localised tumours approximately 90%. However, the risk of 
developing second primary colorectal cancers is higher in survivors, with an estimated 1.4 fold 
increased risk compared to healthy controls. 
 
Physical activity is significantly related to colorectal cancer risk; individuals who engage in higher 
levels of physical activity are at a 26% reduced risk of developing colorectal cancer compared to 
those who engage in lower levels of physical activity. Moreover, there is convincing 
epidemiological evidence to suggest that vigorous activity elicits a greater risk reduction for the 
development of colorectal cancer than activity performed at a moderate intensity. Previous research 
has implicated insulin sensitivity and the insulin-like growth factor (IGF) axis as factors related to 
the risk of colorectal cancer. The aim of this study was to investigate the influence of exercise 
intensity on insulin sensitivity and the IGF axis in colorectal cancer survivors. Twenty-nine men 
and women aged 33 – 82 years completed a 4-week randomised controlled exercise intervention 
incorporating three sessions per week of moderate intensity exercise (MIE) or high intensity 
interval training (HIE). For this trial, the MIE protocol was considered a ‘usual care’ control group 
in the context of physical activity recommendations, given that the exercise demands for those in 
the MIE group align with the current exercise oncology guidelines. Before and after the 
intervention, insulin sensitivity using an oral glucose tolerance test (OGTT), insulin-like growth 
factor-I (IGF-I), and insulin-like growth factor binding protein-III (IGFBP-III) were measured. 
Peak cardiorespiratory (VO2peak) test, fat mass, lean mass, and body fat percentage were also 
measured pre- and post-intervention. HIE significantly improved 120 min glucose readings from the 
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OGTT following the 4-week intervention (-7.1%, p = 0.037). No significant (p > 0.05) between- or 
within-group changes were found for other measures of insulin sensitivity, IGF-I, or IGFBP-III. 
VO2peak significantly increased in both the HIE (+23.0%, p = 0.013) and MIE group (+1.7%, p = 
0.025) with training, with no significant between-group differences (p = 0.124). In the HIE group 
only, significant changes were found for fat mass (-3.3%, p ≤ 0.001), lean mass (+1.8%, p ≤ 0.001), 
and body fat percentage (-3.3%, p ≤ 0.001) following the intervention.  There were no significant (p 
> 0.05) changes in body composition for the MIE group. 
 
The absence of change in insulin sensitivity and the IGF axis following the exercise interventions 
are likely due to baseline values in these measures falling within ranges described in healthy 
persons. The significant training-induced changes in VO2peak, fat mass, lean mass, and body fat 
percentage observed in the HIE group are potentially clinically meaningful, as improvements in 
these markers have previously been associated with reduced cancer specific- and all cause-
mortality. The present study has shown that HIE is a safe and effective mode of exercise for rapidly 
improving cardiorespiratory fitness and body composition, but not insulin sensitivity or the IGF 
axis, in colorectal cancer survivors.    
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CHAPTER 1  GENERAL INTRODUCTION     
 
Colorectal cancer is the second most prevalent cancer in both men and women in Australia and has 
the second highest burden of disease of all cancers (1). Physical inactivity has a significant 
influence on colorectal cancer development; at least 15% of all colorectal cancer cases can be been 
attributed to insufficient physical activity (2). Supporting this, individuals who engage in higher 
levels of physical activity (>21 MET hours per week) are at a 24% reduced risk of developing 
colorectal cancer compared to those who engage in lower levels of physical activity (<2 MET hours 
per week) (3,4). Given that colorectal cancer survivors have a 1.4 fold increased risk for the 
development of second primary colorectal cancers compared to healthy persons (5), physical 
activity should be considered an essential adjuvant therapy for this population. 
 
Physical activity has been shown to improve cardiovascular fitness and body composition in 
colorectal cancer survivors (6-8). Improvements in these measures are synonymous with decreased 
disease recurrence and lower mortality rates in this population (2). Specifically, there is convincing 
epidemiological evidence to suggest that vigorous activity (>85% of peak heart rate) is associated 
with a lower risk of colorectal cancer-specific mortality compared to moderate intensity (50-70% of 
peak heart rate) activity (9-11). Despite these findings, the optimal intensity of physical activity for 
preventing the development of colorectal cancer and reducing disease-specific mortality are yet to 
be established. This is, at least in part, due to an incomplete understanding of the biological 
mechanisms linking physical activity to colorectal cancer development and disease-specific 
mortality.  
 
One mechanism that could potentially explain the relationship between physical activity and 
colorectal cancer risk is the insulin-like growth factor (IGF) axis; a family of proteins known to be 
associated with colorectal cancer pathology. Specifically, the IGF axis is believed to influence 
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cellular growth, proliferation regulation, differentiation and apoptosis (12,13). In light of this 
biological relationship, hyperinsulinemia has been implicated as a key host factor in colorectal 
cancer development due to the physiological similarities between insulin and the IGF axis (12,13). 
Insulin sensitivity, IGFs and their binding proteins have thus been a key research focus in colorectal 
cancer pathology (14).   
   
The presence of diabetes in colorectal cancer survivors has been positively associated with 
heightened disease-specific mortality, with a relative risk of 1.36 compared to those who are non-
diabetic (15). The insulin-like growth factor-1 (IGF-I) receptor is 60% homologous to the insulin 
receptor and is thus able to bind the insulin molecule and initiate cellular proliferation (16). 
Therefore, hyperinsulinemia leads to greater activation of the IGF-I receptor, and the subsequent 
mitogenic pathways it regulates. Physical activity has consistently been shown to improve insulin 
sensitivity, reduce hyperinsulinemia and the subsequent risk of disease-specific mortality in 
diabetics (17,18).  A similar relationship between physical activity and insulin sensitivity has been 
found in colorectal cancer survivors; reductions in plasma insulin occurred in response to 12 weeks 
of moderate intensity exercise training (19).   
 
Research findings from studies examining the relationship between physical activity and the IGF 
axis in cancer populations is mixed (20-22), however there is evidence showing positive changes in 
components of the IGF axis in response to regular exercise in colorectal cancer survivors (19,23). 
Haydon et al. (24), via prospective analysis of colorectal cancer-specific mortality, reported that a 
one standard deviation increase in  insulin-like growth factor binding protein-III (IGFBP-III) was 
associated with a 51% reduction in premature mortality for those who were physically active. This 
association was not seen for inactive individuals (24). The researchers did not provide details 
relating to the specific intensity of exercise.  
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Recently, Lee et al. (19) measured changes in IGF-I and IGFBP-III following a 12-week home-
based exercise intervention in colorectal cancer survivors. An increase in IGFBP-III was found in 
response to the intervention. To date, the aforementioned studies are the only ones to have 
examined the relationship between physical activity, insulin sensitivity and the IGF axis in 
colorectal cancer survivors. Research involving tightly controlled exercise interventions will 
advance understanding of the relationship between insulin sensitivity, the IGF axis and the risk of 
development of colorectal cancer.  The ‘Colon Health and Life-Long Exercise Change’ 
(CHALLENGE) trial (25) is currently addressing this research gap. This ongoing randomised 
controlled trial incorporating a multicentre physical activity intervention is utilising instrumented 
measures of physical activity and aerobic fitness for people with stage II and III colon cancer. The 
primary outcomes of the CHALLENGE trial are disease-free survival and identification of key 
biological markers (insulin, insulin-like growth factors, and selected cytokines) believed to 
underpin the relationship between physical activity and survival after colorectal cancer diagnosis.  
 
Emerging evidence suggests that high intensity exercise (HIE) is more effective than moderate 
intensity exercise (MIE) for improving insulin sensitivity in clinical populations characterised by 
impaired glucose control (17,26). This type of exercise training has proven to be safe and effective 
in cancer populations, with a reported 70% adherence to a high intensity exercise intervention, and 
no adverse events (27).  It is therefore plausible that high intensity interval exercise may elicit 
superior improvements in insulin sensitivity in colorectal cancer survivors compared to moderate 
intensity exercise. The IGF axis is yet to be measured in response to high intensity interval training.    
 
The aim of the study described in Chapter 3 of the present thesis was to compare the effect of high 
intensity interval training and moderate intensity exercise training on insulin sensitivity and the IGF 
axis in colorectal cancer survivors. It was hypothesised that high intensity interval training would 
result in greater increases in insulin sensitivity and IGFBP-III, and a greater reduction in IGF-I 
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compared to moderate intensity exercise training. Available evidence shows volumes of exercise 
that meet the current exercise oncology will reduce the risks of colon cancer.  What is not clear is 
whether exercise completed at higher intensities to those aligned with current guidelines can confer 
potentially greater health benefits. Body composition and cardiorespiratory fitness were also 
assessed before and after the training programs to identify potential relationships between changes 
in insulin sensitivity, the IGF axis and these measures of health.  
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CHAPTER 2  REVIEW OF LITERATURE      
 
2.1 Introduction  
Of all cancers, colorectal cancer has the fourth highest incidence rate worldwide and it is estimated 
that colorectal cancer is responsible for the deaths of approximately 608,000 people each year (1). 
Due to improved detection and treatment protocols, mortality from this disease has decreased in 
recent years, with 5-year survival rates for localised tumours around 90% (28). However, the risk of 
second primary colorectal cancers in colorectal survivors is heightened up to 1.4 fold compared to 
healthy controls (5). Given this, preventing the development of primary colorectal cancers in 
current survivors is a public health priority.  
 
Physical activity has been significantly associated with the prevention of colorectal cancers, 
whereby individuals who are physically active (>22 MET hours per week) have a 24% reduced risk  
of developing the malignancy compared to those who engage in lower levels of physical activity 
(<2 MET hours per week) (4). Further, epidemiological data show a significant decrease in disease-
specific mortality for individuals who are physically active after diagnosis compared to those who 
are not (29,30). Though the biological mechanisms that underpin this association are not entirely 
clear, insulin and the IGF axis may be involved.  
 
Insensitivity to insulin underpins the pathology of diabetes; a biological marker that responds 
favourably to physical activity. Diabetics have a 1.2-1.5 fold increased risk for the development of 
colorectal cancer compared to those without diabetes (31,32). Risk of mortality from colorectal 
cancer is also heightened (1.4 fold) in diabetics compared to non-diabetics (31,32). These 
associations premise investigation into the physiological connection between insulin, physical 
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activity and the development of second primary colorectal cancers. Due to its functional similarity 
to insulin, the IGF axis has also been implicated as a key host pathway potentially responsible for 
the association between physical activity and colorectal cancer (33-35).  
 
Physical activity may represent an effective means of eliciting favourable changes in the insulin 
molecule and the IGF axis in colorectal cancer survivors. Presently, there is an absence of research 
investigating the effects of structured physical activity interventions on these biomarkers in 
colorectal cancer survivors. Available evidence surrounding the influence of physical activity on the 
development of colorectal cancer, insulin and the IGF axis will be reviewed in subsequent sections 
of this chapter. 
 
2.2 Physical activity is protective for the development of primary colorectal 
cancers 
An inverse relationship between physical activity and risk of developing colorectal cancer has been 
consistently reported in the literature (4,36,37). For those who are physically active (>22 MET 
hours per week), meta-analyses have calculated a 20-30% risk reduction for developing colorectal 
cancer compared to inactive persons (4,36,37). Furthermore, engaging in physical activity after 
colorectal cancer diagnosis is associated with a 50-60% reduction in disease-specific mortality 
(23,38-40). Comparatively, colorectal cancer patients who receive chemotherapy benefit from 40-
50% reductions in mortality compared to those who receive surgery alone (41). With this in mind, 
physical activity is an essential therapy both for the prevention of colorectal cancer development, 
and reduction in mortality risk for those already diagnosed with the disease. Despite this 
recommendation, there is still much uncertainty surrounding the optimal prescription of physical 
activity required to elicit these changes. 
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2.2.1 Physical activity in the prevention of colorectal cancer 
Over the past ten years, three meta-analyses (4,36,42) have confirmed an inverse relationship 
between both leisure time and occupational physical activity, and the risk for developing colon 
cancer. Samad et al. (36) analysed 19 cohort and 28 case-control studies and identified a relative 
risk for developing colon cancer when comparing the most to the least active individuals, of 0.78 
and 0.79 in men for leisure time and occupational physical activity, respectively. For women, a 
relative risk for developing colorectal cancer of 0.71 was identified for leisure time physical activity 
only compared to no physical activity. More recently, Wolin et al. (4) found a lower relative risk for 
developing colorectal cancer (0.76) in both men and women when comparing the most to least 
active individuals. In the study by Wolin et al. (4), activity levels in the most active group equated 
to approximately 5-6 hours of brisk walking per week, whereas the least active group performed 
approximately 0.5 hours of brisk walking per week. The levels reported in the most active group (5-
6 hours of brisk walking per week) are significantly greater than the current physical activity 
recommendations for cancer survivors, which advocate 1.5 hours of brisk walking (or equivalent) 
per week (43). For the prevention of colorectal cancer, greater quantities of physical activity than 
what is currently recommended may be required. This is of particular importance to colorectal 
cancer survivors who have a heightened risk (1.4) for the development of second primary colorectal 
cancers compared to healthy persons (5). 
 
A meta-analysis by Boyle et al. (37) highlights the position that ‘more is better’,  reporting an 
inverse dose-response relationship between physical activity level and colorectal cancer risk in 9 of 
the 13 studies included in their analysis. Apart from increasing the duration of physical activity, 
‘dose’ can be modulated through activity intensity, whereby higher intensity activity upturns the 
overall dose. Three case-control studies (9,44,45) have highlighted a greater risk reduction for the 
development of colorectal cancer with vigorous intensity physical activity compared to moderate 
intensity activity. Boyle et al. (44) further supports the ‘dose response’ relationship reporting a 
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superior effect for >18 MET-hours per week (hazard ratio = 0.45, 95% CI = 0.24-0.85) compared to 
6-18 MET-hours (hazard ratio = 0.51, 95% CI = 0.29-0.91) and <6 MET-hours (hazard ratio = 1.05, 
95% CI = 0.64-01.71) of physical activity per week (Ptrend=0.006).  
 
The findings outlined above are promising for the prescription of high intensity, over moderate 
intensity physical activity in the prevention of colorectal cancer development. In light of the 
heightened risk of second primary cancers in colorectal cancer survivors (5), high intensity activity 
may also be beneficial for persons who have survived the disease. This is yet to be investigated in a 
controlled intervention. Given the substantial time and sample size requirements needed to measure 
colorectal cancer development as a primary outcome, it may be more feasible to initially investigate 
the impact of exercise intensity on biological markers that have been linked to the development of 
the disease. These will be discussed in section 2.3 of this review.  
 
2.2.2 Physical activity in the prevention of colorectal cancer-specific mortality 
Following conventional treatment, colorectal cancer survivors who remain or become physically 
active have a 50%-60% reduction in cancer-specific mortality compared to those who are inactive 
(38-40). Indeed, physical activity is recommended as an adjuvant to conventional treatment for 
those having been diagnosed with the disease (4,23,36,38-40,42).  
 
Meyerhardt et al. (38) found an inverse relationship (p = 0.0002) between physical activity and 
colorectal cancer-specific mortality in male survivors. In a cohort of 661 men, engaging in more 
than 27 metabolic equivalent of task (MET) hours of physical activity per week was associated with 
a decreased risk of colorectal cancer-specific death (hazard ratio = 0.47, 95% CI = 0.24-0.92) 
compared to those who engaged in less than 3 MET hours per week (38). In a cohort of 573 female 
colorectal cancer survivors, a relative risk of 0.39 was found for those who engaged in at least 18 
MET hours of physical activity per week compared to those who engaged in less than 3 MET hours 
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per week (39). Both studies found adjustment for cancer stage (I-III), body mass index and pre-
diagnosis levels of physical activity did not affect the relationship. These robust findings highlight 
the importance of physical activity following diagnosis irrespective of pre-diagnosis activity levels. 
Although the specific intensity of physical activity required for reductions in colorectal cancer-
specific mortality is not known, Meyerhardt et al. (38) indicated that a protective effect for 
colorectal cancer-specific mortality is likely to occur at approximately 9 MET hours per week. This 
volume of physical activity aligns well with the current physical activity recommendations for 
cancer survivors (43).   
 
The majority of studies to have investigated the relationship between physical activity and 
colorectal cancer survival have not reported the intensity of activity performed by the participants 
(4,23,36,38-40,42). Rather, MET values have been reported, which are an amalgamation of 
frequency, duration and intensity of activity. To a large part, this can be attributed to the limitations 
of self-recall physical activity measures used in these studies, which typically estimate activity 
levels using assignment of MET values to specific tasks. Additionally, participants are more likely 
to over-report than under-report when recalling previous activity levels (46). This limits the 
conclusions that can be drawn from studies with respect to the optimal intensity of physical activity 
required to elicit a protective effect for colorectal cancer-specific mortality.  
 
Research that involves structured physical activity interventions is required to better understand the 
relationships between colorectal cancer-specific mortality and physical activity. Particularly, these 
studies need to place a central focus on activity intensity, and how this variable implicates 
mortality. As discussed in section 2.2.1, there are difficulties associated with measuring mortality as 
a research outcome; namely, time required to track mortality. Rather, the measurement of biological 
markers that have been previously linked to disease-specific mortality in colorectal cancer survivors 
could be used as surrogate measures. The results from the previously mentioned CHALLENGE 
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trial (which will measures both biomarkers and mortality in response to a physical activity 
intervention for colorectal cancer survivors) will be extremely useful in supporting these insights.   
 
2.2.4 Section summary 
Physical activity has been consistently linked to a decreased risk for the development of colorectal 
cancer (4,36,37), and reductions in disease-specific mortality following diagnosis. Further, a dose-
response relationship has been reported between physical activity and the development of colorectal 
cancer (44). This adds weight to the claim that high intensity activity (a derivative of activity dose) 
is more beneficial than moderate activity for the prevention of colorectal cancer development, and 
disease-specific mortality following diagnosis (9,44,45).  
 
2.3 Insulin sensitivity and the insulin-like growth factor axis 
Diabetes, which is characterised by insulin resistance, has been linked to the development of 
colorectal cancer (47,48).  Further, individuals with colorectal cancer who also have diabetes have 
higher mortality rates compared to individuals who have colorectal cancer but not diabetes (49,50). 
In light of the already elevated risk for the development of second primary cancers in colorectal 
cancer survivors, insulin control in this population is an essential therapeutic target to limit the 
development of second cancers. Given this, investigating the effect of physical activity on insulin 
resistance and sensitivity in colorectal cancer survivors is warranted.  
 
The IGF axis may also be involved in the relationship between physical activity, risk for developing 
colorectal cancer and disease-specific mortality (2,3). Specifically, the IGF axis plays a central role 
in cellular growth, proliferation regulation, differentiation and apoptosis (12,13). At a structural 
level, the insulin molecule bears a similar resemblance to certain members of the mitogenic IGF 
axis, specifically IGF-I. This allows the insulin molecule to initiate similar growth processes within 
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cancerous cells (12,13). Given these mechanisms, insulin, IGFs and their binding proteins have 
been identified as a key research focus in colorectal cancer pathology (14).  
 
2.3.1 Physiology and mechanics of insulin and the insulin-like growth factor axis 
The IGF axis consists of two polypeptide ligands (IGF-I and IGF-II), two cellular membrane 
receptors (IGF-IR and IGF-IIR), and six binding proteins (IGFBP-1 through IGFBP-6). IGF-I and 
IGF-II are produced via the endocrine, paracrine and autocrine systems (51). Growth hormone (GH) 
plays a dominant role in the upregulation of IGF-I with serum levels peaking around puberty and 
then decreasing throughout life (52,53). IGF-I levels are also influenced by sex and nutritional 
status with higher levels found in women (54), during periods of excess energy intake (55) and with 
obesity (52). Unlike IGF-I, the release of IGF-II is GH independent and levels remain stable after 
puberty (51). At a cellular level, IGF-I and IGF-II accelerate cell cycle progression through the 
growth phase where DNA replication occurs (56). Analogous to this growth-facilitating effect, IGF-
I and IGF-II have the capacity to block cellular apoptosis. These processes have been reported in 
healthy (16) and malignant tissue (57), highlighting the potential role of IGF-I and IGF-II in the 
progression of colorectal cancer following diagnosis. 
 
The biological actions of IGF-I and IGF-II are mediated via two cell-surface receptors; IGF-IR and 
IGF-IIR (16). Because of the structural similarities between IGF-I and IGF-II, the IGF-IR is able to 
bind both molecules albeit at different affinities. IGF-IR favours IGF-I, binding the molecule at a 2-
15 fold higher affinity than IGF-II (58). Unlike the IGF-IR, the IGF-IIR does not bind IGF-I; this 
receptor specifically binds IGF-II, and at a 500-fold affinity greater than the IGF-IR (13). Because 
binding of IGF-II to the IGF-IIR results in degradation of the molecule, the intra-cellular actions of 
IGF-II are thought to be primarily mediated through the IGF-IR (59). This complex association 
underpins the uncertainty that exists for the role of the IGF axis within the relationship between 
physical activity and colorectal cancer.  
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The IGF-I receptor is 60% homologous to the insulin receptor and is able to bind the insulin 
molecule, albeit with a 1000-fold lower affinity than for IGF-I (16). Activation of the IGF-I 
receptor by the insulin molecule has the capacity to initiate downstream processes of cellular 
differentiation, proliferation and anti-apoptosis; mechanisms that have all been implicated in 
colorectal cancer prognosis (34). This pathway therefore recognises a biological link between 
hyperinsulinemia, insulin insensitivity and the IGF axis mediated pathways by which colorectal 
cancer is thought to develop and propagate.  
 
It has been reported that insulin interaction with the IGF-I receptor only occurs at supraphysiologic 
levels, which may be far above what is observed even in hyperinsulinemic persons (34). What may 
be more apparent is an increase in plasma IGF-I and IGF-II as a result of hyperinsulinemia which, 
in turn, activates their respective receptors and initiates mitogenic behaviour within cancerous cells 
(60-62).  
 
The majority (~75%) of IGF-I and IGF-II produced via the endocrine system are bound in a ternary 
complex with IGFBPs and an acid labile subunit (ALS) (63). The remaining IGF-I and IGF-II 
circulate in free form or in a binary unit with IGFBPs only (63).  Because ALS only has an affinity 
for IGF-I/IGF-II that is bound in a IGFBP complex, IGFBPs are thought to control the 
bioavailability of IGF-I and IGF-II (64). Regulation of IGFs is achieved via three distinct pathways; 
1) transportation, 2) prolonging the half-life of IGFs and protecting them from degradation, and 3) 
modulating the interaction between IGFs and their receptors (65). When combined in the ternary 
unit, IGF-I and IGF-II are unable to bind to the cell surface receptors, IGF-IR and IGF-IIR. This is 
due to the ~50 fold higher affinity of IGFBPs for IGF-I and IGF-II over their respective receptors 
(65). The outcome of this affinity is thought to be the inhibition of IGF receptor activation, which in 
turn prevents IGF-I and IGF-II mediated cellular proliferation and enhances apoptosis. In contrast, 
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IGFBPs prolong the half-life of IGF-I and IGF-II via the prevention of proteolytic degradation that 
would normally occur if IGF-I and IGF-II were circulating in isolation (63). This results in a 
lengthening of IGF-I and IGF-II bioavailability (66). Given these differing processes, IGFBPs can 
facilitate or inhibit the mitogenic actions of IGF-I and IGF-II. These mechanisms indicate that 
IGFBPs may be of similar importance to IGF-I and IGF-II in mediating cellular growth and 
understanding how physical activity influences colorectal cancer incidence and mortality.  
 
In serum, IGFBP-III is the most abundant IGF binding protein, carrying approximately 90% of all 
bound and free circulating IGF-I and IGF-II (34). Independent to its association with IGF-I and 
IGF-II, IGFBP-III has been found to have a pro-apoptotic and anti-proliferative capacity (67). This 
has led to a focus on IGFBP-III as a mediator for the development and progression of colorectal 
neoplasms.  
 
A limitation to the measurement of these biomarkers in existing cancer research is that they may not 
reflect downstream cellular growth. Assays used to measure IGF-I and IGF-II do not discriminate 
between free form IGF-I/IGF-II, and that which is bound in binary and ternary units (64). Because 
of this, current techniques may not reflect the bioactive IGF-I and IGF-II that are able to interact 
with cellular receptors. Furthermore, given that IGFBPs have both growth facilitating and inhibiting 
effects, direct measures of these biomarkers cannot accurately predict pro- or anti-proliferative 
processes. An assay that overcomes these limitations will enhance the understanding of how 
physical activity influences the IGF axis interaction with carcinomas. Identifying the action of 
intracellular growth processes rather than merely measuring circulating levels of these biomarkers 
is needed. Nonetheless, reductions in plasma IGF-I and IGF-II, and increases in IGFBP-III suggest 
a more favourable outcome for the prevention of colorectal cancer development and reductions in 
disease-specific mortality. 
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2.3.2 Epidemiology: insulin sensitivity 
There is consistent evidence supporting a higher risk of colorectal cancer in people with diabetes 
compared to those with normal glucose control. A meta-analysis of 15 studies found a relative risk 
of 1.30 (95% CI = 1.20-1.40) for colorectal cancer development in individuals who were diagnosed 
with diabetes compared to individuals with colorectal cancer who were not diabetic (48).  
 
Beyond the increased incidence of colorectal cancer in people with diabetes, individuals who have 
colorectal cancer with pre-existing diabetes have a higher risk of mortality (49). In a cohort of 1039 
colorectal cancer patients, those with concurrent diabetes had a cancer-specific mortality hazard 
ratio of 1.36 compared to those without diabetes (68). These findings are supported by retrospective 
data from 469 diabetic colorectal cancer patients who had a mortality hazard ratio of 1.24 compared 
to those without diabetes (n=2293) (15). Within this cohort, persons with diabetes had a 5-year 
survival rate of 55.7% compared to 62.2% for those without diabetes.  
 
The association between fasting insulin and glucose, and the incidence of colorectal cancer has also 
been investigated (69). Persons in the highest quartile of fasting glucose and insulin levels were 
reported to have a relative risk of 1.8 and 1.6, respectively, for colorectal cancer development when 
compared to the lowest quartile. Within a cohort of persons with and without recurrent colorectal 
adenomas it was found that persons in the highest quartile of both fasting insulin and glucose had a 
higher risk for recurrent adenomas compared to those in the lowest quartile. Odds ratios for the 
development of these recurrent adenomas for plasma glucose and insulin were 1.56 and 1.49, 
respectively, when comparing the highest versus lowest quartile. Further, longitudinal research has 
identified a predictive relationship between colorectal cancer-specific mortality and markers of 
insulin resistance (70). In a cohort of 718 men with colorectal cancer during 21.5 years of follow-
up, it was found that those with higher levels of insulin resistance (measured via an oral glucose 
tolerance test) had a colorectal cancer-specific mortality hazard ratio of 1.65 compared to those with 
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normal insulin sensitivity. This positive association between diabetes and cancer-specific mortality 
has been reported across numerous cancer populations (71).  
 
The weight of research evidence suggests the insulin molecule plays a central role in colorectal 
cancer pathology. Specifically, insensitivity to insulin increases a person’s risk of developing 
colorectal cancer, and risk of disease-specific mortality for individuals already diagnosed with the 
cancer. 
 
2.3.3 Epidemiology: IGF Axis 
Unlike insulin sensitivity, findings from human in vivo research examining the IGF axis and 
colorectal cancer-specific mortality have produced varying results (14,72-75). These studies have 
focussed on tumour grade and metastasis, where a greater tumour grade and extent of metastasis 
infers a heightened colorectal cancer mortality risk (14,72,73,75,76). Across other cancer 
populations such as breast and prostate, a more consistent positive association between cancer-
specific mortality and the IGF axis has been reported (56,77).  
 
Prospective samples from men and women undergoing a colonoscopy identified high-risk 
adenomas to be positively associated with serum IGF-I and inversely associated with IGFBP-III 
(72). Supporting this, in a cohort of 125 colorectal cancer patients, higher serum concentrations of 
IGF-I were found in those with metastases compared to those with localised colorectal cancer (73). 
Similar associations for IGF-I and adenoma severity were reported by Jacobs et al. (74). IGF-II has 
also been linked to colorectal cancer severity with higher serum levels found in concurrence with 
secondary cancers (14). In contrast to these findings however, no significant differences in serum 
IGF-I were reported with patients who had moderate (adenoma) compared with more advanced 
(carcinoma) colon cancers (75). Nonetheless, the weight of the limited available evidence supports 
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a positive relationship between IGF-I/IGF-II and colorectal cancer-specific mortality and an inverse 
relationship between IGFBP-III and colorectal cancer-specific mortality.  
 
In vitro research has been used to examine markers of the IGF axis after colorectal cancer diagnosis 
to determine the relationship with disease-specific mortality. Wolpin et al. (78) addressed this with 
373 participants over 13 years and found no associations between pre-diagnostic IGF-I and IGFBP-
III concentrations, and mortality in those who developed colorectal cancer. Given that lifestyle 
factors such as diet, obesity and physical activity are known to influence IGFs (52,64), failure to 
include these confounders into the analysis may have contributed to the lack of significant findings 
with regard to IGF-I and IGFBP-III. Following colorectal cancer diagnosis, higher circulating 
IGFBP-III has been correlated with a greater response to chemotherapy, arrested rate of tumour 
progression, and an increase in overall survival (79).  
 
Within animal models, research has identified significant associations between tumour severity and 
IGF-I, IGF-II and IGFBP-III (14,72,73,75,76). IGF-I has been found to influence colon cancer 
tumour growth and metastasis in liver IGF-I deficient (LID) mice, which have approximately 75% 
less endogenous IGF-I than controls (76).  Following transplantation of colon adenocarcinomas, 
LID mice had smaller and fewer tumours with less liver metastases than controls. Further, 
exogenous IGF-I administration in both controls and LID mice increased the rate of tumour 
progression and metastases compared to mice treated with saline (76).  
 
Given the pathways by which IGF-I and IGF-II stimulate cellular proliferation, expression of IGF-I 
receptor (IGF-IR) and IGF-II receptor (IGF-II R) in colonic carcinomas likely influences tumour 
progression. A high presence of these receptors in tissues would allow for enhanced activation of 
intracellular growth via IGF signalling. Positive tissue staining for IGF-IR has been more frequently 
identified in primary and high risk colorectal cancers in comparison to non-cancerous adenomas 
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and normal tissue (80,81). Further research has identified IGF-IR and IGF-IIR gene expression to 
be 2.5 and 4.0 times higher, respectively, in malignant tissue compared to adjacent non-cancerous 
tissue (82). Despite this finding, the IGF-IIR is not thought to influence tumorigenic potential as it 
lacks the capacity to initiate mitogenic behaviours (59). 
 
2.3.4 Section summary 
Epidemiological insights into to the association between diabetes and the development of, and 
mortality from colorectal cancer have identified insulin as a key marker in the pathology of 
colorectal cancer. Bearing structural similarities to insulin, IGF-I and its biological mediator, 
IGFBP-III have also been linked to the development of, and mortality from colorectal cancer in 
numerous population studies.  
 
Reflecting the epidemiological data, in vivo and in vitro research has identified insulin and the IGF 
axis as facilitators of neoplastic growth in the colon and rectum. From a clinical perspective, these 
processes indicate that heightened levels of IGF-I and reduced IGFBP-III and insulin increase ones 
risk for the development of colorectal cancer, and disease-specific mortality in those with a pre-
existing diagnosis.  
 
2.4 Insulin and insulin-like growth factor responses to physical activity  
Reductions in plasma insulin and improvements in insulin sensitivity can occur in response to a 
physical activity interventions in both healthy and clinical populations (83). The response of the 
IGF axis to a chronic exercise exposure is more variable, however reductions in IGF-I and increases 
in IGFBP-III in response to physical activity in cancer populations have been reported (19,20,84).  
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2.4.1 Insulin sensitivity changes in response to physical activity in cancer survivors 
Changes in insulin sensitivity in response to a physical activity intervention re reported in Appendix 
B of this thesis. The only intervention to investigate changes in insulin sensitivity with colorectal 
cancer survivors following a chronic exposure to exercise was published by Lee et al. (19). 
Following 12 weeks of home-based exercise comprising of moderate intensity exercise, such as 
walking, hiking, stationary cycling, swimming and resistance training, fasting plasma insulin 
decreased by ~40% (19). A limitation of this study was that the participants self-monitored their 
exercise intensity.  Given that participants historically over-report rather than under-report their 
activity levels (46), a potential relationship between specific exercise intensity and changes in 
insulin sensitivity could not be accurately assessed in this study.   
 
Due to the lack of research exploring the insulin response to a controlled physical activity 
intervention in colorectal cancer survivors, the evidence from other cancer populations will be 
reviewed. Sixteen weeks of combined aerobic and resistance-based physical activity resulted in 
significant reductions in fasting plasma insulin in a cohort of breast cancer survivors (85). A similar 
trend was found in response to a 26-week aerobic activity-based intervention in breast cancer 
survivors, however this did not reach statistical significance (p = 0.089) (20). Decreases in insulin 
have not been reflected across all interventions that have explored biological responses to physical 
activity in cancer survivors. Following a 26-week resistance training intervention in breast cancer 
survivors, no within-group changes in fasting insulin or insulin sensitivity were reported (22). The 
reason for this disparity may be related to the mode of exercise used. Generally, aerobic-based 
physical activity has resulted in greater reductions in fasting insulin and improvements in insulin 
sensitivity compared with resistance training in healthy persons (83).  
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2.4.2 Insulin-like growth factor axis responses to physical activity 
Similar to the insulin molecule, physiological responses of the IGF axis to physical activity are 
inconsistent; increases, decreases and no change in the IGF axis have been reported in cancer and 
non-cancer populations (20,21,84,86-89) (Appendix B). While the reason for this inconsistency is 
not clear, some researchers believe that negative energy balance may underlie the mechanism/s 
(88), while others purport that it may be more closely related to energy flux (86) and physical 
conditioning (87). Although limited, there is evidence from trials involving colorectal cancer 
populations to indicate that changes in these biomarkers in response to physical activity can have 
favourable outcomes for disease-specific mortality (23).  
 
Only one intervention has investigated the influence of physical activity on the IGF axis in a 
colorectal cancer population. Following 12 weeks of unsupervised physical activity of 18 to 27 
MET-hours per week, significant increases in IGF-I and IGFBP-III were found (19). Given that the 
intervention was unsupervised and adherence to the protocol was measured via a self-reported 
questionnaire, the precise intensity of physical activity required to elicit these changes is unclear. 
This limitation is a reprise of what has been consistently overlooked in physical activity 
interventions for persons with colorectal cancer and/or survivors; a lack of supervision and 
measurement of precise intensity of physical activity. Since participants notoriously over-report 
rather than under-report activity levels, these concerns need to be addressed in future interventions.  
 
Prospective evidence demonstrated that a one standard deviation increase in IGFBP-III was 
associated with a 51% reduction in colorectal cancer-specific mortality for those who were 
physically active (24). The same association was not seen for inactive individuals or for IGF-I (24). 
This indicates that physical activity is capable of eliciting a clinically meaningful shift in disease-
specific mortality that is manifested by a measureable change in IGFBP-III. Whilst it cannot be 
concluded without further research why the IGF-I response did not reflect changes in IGFBP-III, 
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there likely exists a delicate interplay between the IGF axis and other exercise-induced biochemical 
responses.     
 
Research in other cancer types has examined the relationship between the IGF axis and physical 
activity. In a cohort of 26 men diagnosed with prostate cancer and currently receiving androgen 
deprivation therapy, it was found that IGFBP-3 significantly increased and IGF-I significantly 
decreased in men undertaking a six-month resistance training program (21). No significant changes 
in these biomarkers were reported for men in the aerobic training arm. Although no analysis of this 
dissonance was mentioned in the paper, it is interesting to note differences with regard to the 
exercise prescription in both treatment arms. Those in the resistance training group were given a set 
of exercises to complete in the program whereas those in aerobic group were encouraged to exercise 
at 60-80% of their age-predicted maximum heart rate via feedback from a wristwatch monitor. No 
baseline test was completed to confirm this heart rate range, therefore the intensity range completed 
by participants in the aerobic group may have been inadequate to elicit similar changes in the IGF 
axis experienced by the resistance training group.  
 
Several studies have measured the response of IGFs to a physical activity intervention in breast 
cancer survivors. Fairey et al. (84) tracked the changes in IGF-I, IGF-II and IGFBP-III following 15 
weeks of moderate intensity aerobic exercise; significant increases in IGFBP-3 and decreases in 
IGF-I were found, including decreases in their molar ratio, which is thought to reflect bioactive 
IGF-I.  More recent research by Irwin et al. (20) tracked breast cancer survivors over a 6 month 
randomised controlled trial, and found similar results for IGF-I but significant decreases in IGFBP-
III compared to pre-intervention levels. Schmitz et al. (22) investigated the role of resistance 
training on the IGF axis in breast cancer survivors. Six months of resistance training resulted in 
significant reductions in IGF-II however no significant changes in IGF-I were reported. Compared 
to Fairey et al. (84), a higher percentage of participants in this study were undergoing 
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chemotherapy, which is known to alter IGF-I levels and therefore may have muted the biochemical 
response to physical activity. 
 
2.4.3 Confounds to the insulin sensitivity and insulin-like growth factor response to physical 
activity  
In addition to physical activity, negative energy balance through dietary restriction may lead to a 
improvement in insulin sensitivity (90) and a reduction in IGF-I (55).  Several studies involving 
healthy populations have attempted to address this by employing rigorous dietary controls in 
addition to a physical activity intervention. Nemet and colleagues (88) found IGF-I only decreased 
following seven days of aerobic exercise when participants were in a negative energy balance 
(assisted via dietary restriction). In contrast, plasma insulin decreased in both positive and negative 
energy balance groups, highlighting that physical activity was enough stimulus to elicit a response 
in this group (88). Smith et al. (91) found no differences in IGF-I between two groups who 
experienced the same negative energy balance through physical activity or diet alone. These 
findings are in contrast to those of Smith et al. (91), further confounding the relationship between 
physical activity and the IGF axis in particularly.  
 
Given that dietary intake influences insulin sensitivity and IGF-I levels, controlling for this variable 
in the days preceding testing is crucial to understanding the precise impact of physical activity on 
the IGF axis (55). Many of the studies investigating the physical activity/IGF association 
(20,21,84,86-89) (Appendix B) have not reported dietary intake control prior to testing. Further, 
redistribution of body composition may be fundamental to changes in insulin and the IGF axis that 
occur following a physical activity intervention. Chronic exposure to physical activity has 
repeatedly been associated with changes in body composition in cancer survivors. Namely, an 
increase in lean body mass and/or a decrease in fat mass, depending on the type of activity utilised 
during the intervention (92,93).  
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Presently there is limited evidence investigating associations between lean and fat mass with 
changes in insulin sensitivity and the IGF axis in cancer survivors. Following a 15-week resistance 
training intervention in 30-50 year old women, lean mass increased significantly and fat mass 
decreased significantly compared to baseline (22). This change occurred concurrently with a 
decrease in fasting insulin and total IGF-I. Unfortunately, no p-value was reported for this 
correlation. Following a combined physical activity and dietary intervention, underfed individuals 
who experienced significant losses in fat mass (p < 0.0005) also showed significant decreases in 
insulin (p < 0.044) and IGF-I (p < 0.0005) (88). Total body mass change was positively correlated 
with IGF-I (R = 0.65, p < 0.02); unfortunately no distinction was made between fat and lean mass 
in this sub-analysis. In light of available evidence, future interventions should consider potential 
changes in both lean and fat mass when interpreting insulin sensitivity and IGF axis responses to 
physical activity. 
 
2.4.4 Section summary 
The evidence reviewed above highlights insulin and the IGF axis as potential biological mediators 
linking physical activity to the development of colorectal cancer, and disease-specific mortality in 
persons already diagnosed with the disease. Decreases in plasma insulin and IGF-I, and increases in 
IGFBP-3 in response to a physical activity intervention have the potential to reduce the risk of 
second primary colorectal cancers in colorectal cancer survivors, along with disease-specific 
mortality in this population. Changes in fat and lean body mass in response to exercise training may 
also be related to changes in these biological markers and to risk of colorectal cancer development 
and mortality.  
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2.5 High intensity exercise  
High intensity exercise has, in recent years, attracted the attention of researchers involved in the 
management and prevention of a number of chronic diseases. Indeed, high intensity exercise has 
emerged as an effective means of improving functional capacity and health in persons with type II 
diabetes, primarily via changes in insulin sensitivity (17). These improvements in insulin sensitivity 
have been identified following as little as two weeks of high intensity training (17,18).  
 
Although adopting different training protocols and methods of analysis, the available research 
highlights a superior effect of high intensity exercise over moderate intensity exercise for 
improvements in fasting insulin and insulin sensitivity (26,94-96) (Appendix B). Within clinical 
populations such as type II diabetes, coronary artery disease and heart failure, the ‘4x4’ high 
intensity exercise approach (97) has been most commonly utilised, and shown to be safe (26,97-99). 
Specifically, no adverse events have been reported in response to this mode of training (26,97-99). 
This protocol involves exercising at 85-95% of a person’s peak heart rate for four minute intervals 
interspersed with three minute periods of active recovery (including warm-down following the forth 
interval) at 50-70% of peak heart rate (97). This combination repeats four times with the inclusion 
of a 10-minute warm-up, to total 38-minutes of exercise.  
 
Although the aforementioned ‘4x4’ protocol is yet to be utilised in cancer populations, Adamsen et 
al. (27) investigated the effect of a six week high intensity exercise intervention with 269 cancer 
survivors. The intervention incorporated three 90-minute sessions of combined resistance and 
aerobic training. The resistance-training component required participants to complete 3 sets of 8 
repetitions at 70% of their 1-repetition maximum weight. Aerobic training involved intervals on a 
stationary bike at 85-95% of each participant’s maximum heart rate, similar to the ‘4x4’ protocol 
described above (26,97-99). The intervention group reported a 10.7% improvement in 
cardiorespiratory fitness measured via a maximum oxygen uptake (VO2max) test after six weeks of 
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training; no changes were reported in the control group. Further, muscular strength improved by 
29.6% in the intervention group, although this was not reflected by changes in lean mass. No 
changes in muscular strength were reported in the control group. Additionally, the intervention 
group reported no adverse events and a 70% adherence rate. This study provides preliminary 
support for the safety and feasibility of high intensity exercise in cancer survivors.   
 
In light of the reviewed evidence, a high intensity exercise intervention over as few as two weeks 
may improve insulin sensitivity. Further, it is plausible that high intensity exercise may deliver 
superior improvements in insulin sensitivity and the IGF axis compared to moderate intensity 
exercise. Whether these aforementioned changes in response to high intensity exercise occur in 
colorectal cancer survivors remains to be elucidated. Increases in insulin sensitivity and IGFBP-III, 
and decreases in IGF-I, indicate clinically meaningful responses such as a reduced risk for the 
development of colorectal cancer, along with decreased mortality in persons already diagnosed with 
the disease. Given that the current physical activity recommendations for cancer survivors 
recommends 150 minutes of only ‘moderate intensity’ exercise per week (43), the benefits of brief, 
high intensity exercise needs to be explored.  
 
2.6 Summary 
While the benefits of physical activity for reduction in disease-specific mortality following 
colorectal cancer diagnosis are well established, the physiological mechanisms by which physical 
activity can mediate these outcomes remain to be determined. Of the several biological pathways 
that may be involved, insulin and the IGF axis are the most plausible mechanisms and have 
subsequently received the most interest. Following diagnosis from colorectal cancer, there is 
evidence to suggest that a decrease in IGF-I and an increase in IGFBP-III can reduce disease-
specific mortality. In addition, the insulin molecule bears a strong structural similarity to IGF-I, and 
therefore has the capacity to mediate colorectal cancer-specific survival. Given that colorectal 
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cancer survivors who have diabetes are at a heightened risk of disease-specific mortality, improving 
insulin sensitivity through physical activity also warrants investigation.  
 
Evidence from epidemiological studies have highlighted that high intensity physical activity has a 
greater protective effect for the development of colorectal cancer compared to moderate intensity 
activity. This is of particular importance to colorectal cancer survivors, given their increased risk of 
second primary colorectal cancers compared to healthy persons.  
 
There is evidence to suggest that physical activity may influence insulin sensitivity, IGF-I and 
IGFBP-3 in persons with colorectal cancer. Further, IGF changes in response to physical activity 
have been associated with significant reductions in disease-specific mortality for persons with 
colorectal cancer. Despite these encouraging findings that explore the nexus between physical 
activity, insulin and the IGF axis, and colorectal cancer, the evidence is still limited and 
inconsistent. Intervention studies involving a structured high intensity physical activity regime for 
colorectal cancer survivors that examine changes in insulin sensitivity and IGF-I, IGFBP-III are 
clearly warranted.  
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CHAPTER 3  RANDOMISED CONTROLLED TRIAL   
 
3.1 Introduction  
Of all cancers, colorectal cancer has the fourth highest incidence rate worldwide and it is estimated 
that colorectal cancer is responsible for the deaths of approximately 608,000 people each year (1). 
Due to improved detection and treatment protocols, mortality from this disease has decreased in 
recent years, with 5-year survival rates for localised tumours around 90% (28). However, the risk of 
second primary colorectal cancers in colorectal survivors is heightened compared to healthy 
controls, with an estimated risk reported to be up to 1.4 fold (5).  Given this, preventing the 
development of primary colorectal cancers in current survivors is a public health priority.  
 
Physical inactivity has a significant influence on colorectal cancer development; at least 15% of all 
colorectal cancer cases have been attributed to insufficient physical activity (2). There is convincing 
epidemiological evidence to suggest that vigorous activity elicits a greater risk reduction for the 
development of colorectal cancer than activity performed at a moderate intensity (9-11). Despite 
these findings, the optimal intensities of physical activity for preventing the development of 
colorectal cancer are yet to be established. This limitation is, at least in part, due to an incomplete 
understanding of the biological mechanisms linking physical activity to colorectal cancer 
development and disease-specific mortality.  
 
The IGF axis is believed to influence cellular growth, proliferation regulation, differentiation and 
apoptosis (12,13). Further, poor insulin sensitivity has been implicated as a key host factor in 
colorectal cancer development due to the physiological similarities between insulin and the IGF 
axis (12,13). These biological markers are yet to be examined in response to a regimen of high 
intensity physical activity in colorectal cancer survivors.  
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The aim of this study was to compare the effect of different exercise intensities on insulin 
sensitivity and the IGF axis in colorectal cancer survivors. Secondary measures such as body 
composition and cardiorespiratory fitness were measured to enable investigation of potential 
relationships among insulin sensitivity, the IGF axis and previously validated measures of health in 
colorectal cancer survivors. It was hypothesised that HIE would result in superior improvements in 
insulin sensitivity, the IGF axis, body composition and cardiorespiratory fitness compared to MIE.  
 
  
  28 
3.2 Methods 
3.2.1 Study design  
This study was a 4-week randomised controlled trial of high intensity and moderate 
intensity exercise in colorectal cancer survivors. The data for this study were extracted 
from a longer intervention assessing identical physiological markers (along with 
psychosocial markers) over a period of 12-weeks. The details of this intervention are 
described on the Australian and New Zealand Clinical Trials Registry 
(ACTRN12615000908538). Participants were stratified according to age and gender 
before being randomly assigned to: 1) a 4-week program of HIE on a cycle ergometer, or 
2) a 4-week program of MIE on a cycle ergometer. Computer generated randomisation 
was performed by a researcher not involved with the testing or training aspects of the 
study. The allocation ratio for the HIE and MIE groups was 2:1. This randomisation ratio 
was implemented for two reasons: firstly to account for a potentially higher dropout rate 
(approximately 20%) in the HIE group as the feasibility of HIE in this population has not 
been reported; and secondly to allow for appropriate sample sizes for outcomes included 
in the larger trial as described above. Dropout refers to withdrawal of participants from 
the intervention following randomisation and prior to the final testing session. Assuming 
a similar dropout in our study, this would allow us to maintain equal numbers in the 
groups for the final analysis. Group allocation was concealed from the tester and 
participant until after baseline testing was completed.  
 
3.2.2 Participants 
Women and men who had been diagnosed with colorectal cancer and were living in 
southeast Queensland, Australia were invited to participate in the study. Inclusion criteria 
were as follows:  
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Participants must have been: 
i. Diagnosed with colon and/or rectal cancer at some point in their lifetime. 
ii. Over the age of 18 years. 
iii. Not medicated with exogenous insulin or taking insulin-sensitising medication. 
iv. Free of any musculoskeletal, neurological, respiratory, metabolic or 
cardiovascular conditions that may have prevented safe completion of the exercise 
demands of the study. This criterion was determined via screening of the 
participants’ medical history form and general practitioner consent form. 
v. Completed treatment at least one month prior to commencing baseline testing and 
anticipated not undergoing further treatment for the 8-week duration on the study. 
3.2.3 Recruitment Procedures 
Participants were recruited from an existing Cancer Council Queensland (CCQ) 
colorectal cancer registry. Eligibility according to criteria ‘i’, ‘ii’ and ‘v’ as outlined 
above was determined during registry case screening by the CCQ. The Principal 
Investigator (Andrew Sax) determined eligibility according to inclusion criteria ‘iii’ and 
‘iv’ during phone contact with the individual.  
 
Phase one of recruitment: August 2013-January 2014 
1. In collaboration with the CCQ, participants were recruited from an existing cohort of 
colorectal cancer survivors who participated in a longitudinal study exploring quality of 
life in colorectal cancer survivors (101). This study has been in progress for the past 6 
years.  The cohort was initially matched with mortality records from the Queensland 
Cancer Registry to identify members who had died. A letter introducing the study 
(Appendix C) and inviting participation was then sent to potential participants by 
Professor Joanne Aitken, the Principal Investigator of CCQ’s longitudinal study. CCQ 
did not provide names or contact details of any cohort member directly to The 
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University of Queensland researchers for this study. Colorectal cancer survivors who 
were interested in participating in the study were invited to contact the Principal 
Investigator directly at The University of Queensland.  Reasons for participant inclusion 
and exclusion as a result of this recruitment process are shown in Figure 1.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Consort diagram outlining responses from phase one of recruitment. Reasons for 
non-involvement in the study as reported by individuals who contacted the principal study 
investigator include; Distance – individual commented that the location of the intervention 
was too far from their place of residence, Medication – individual was taking medication 
that made them ineligible to participate, Time – individual was unable to commit to the time 
requirements of the study, Intensity – individual stated that they believed that the intensity of 
the exercise involved in the study would be too great for them. CCQ; Cancer Council 
Queensland.  
CCQ!letters!of!invite:!276!Phone!responses:!43!
Randomised:!5! Declined!to!Participate:!38!
Distance:!21!
Medication:!1!
Time:!12!
Intensity:!4!
Email!responses:!22!
Randomised:!7! Declined!to!Participate:!15!
Distance:!7!
Medication:!0!
Time:!4!
Intensity:!0!
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Phase two of recruitment: April 2014-October 2014 
1. CCQ Cancer Helpline: Cancer Council Helpline staff identified potential participants who 
fulfilled the inclusion criteria above during phone calls, provided a brief explanation of the 
study and asked them to consider participating in the study. Callers who expressed an 
interest were mailed a study information flyer (Appendix D) from the Head of Research at 
CCQ. The information flyer included details and instructions for contacting the Principal 
Investigator to discuss the study details, eligibility criteria and their possible participation.  
 
2. Queensland Cancer Registry: This is a population-based register including all 
individuals diagnosed with cancer in Queensland since 1982. For the purposes of this 
phase of recruitment within the study, details of participants diagnosed with colorectal 
cancer from 2011 onwards only were drawn from the registry. Further, southeast 
Queensland residents only (postcodes 4000-4207, 4300-4305, 4500-4519) were 
extracted from the database via this recruitment pathway as the primary reason for non-
involvement by participants contacted through ‘Phase one’ of recruitment was too great 
a travelling distance (Figure 2). All cases were extracted from the database in April 
2014. Cases were then checked against the CCQ death register to ensure no deceased 
patients were selected. Finally, cases were checked against the names of the individuals 
contacted during phase 1 of recruitment to avoid unnecessarily contacting an individual 
a second time.  
Once case extraction was completed, patient names and the names of their treating doctor 
were obtained from the Queensland Cancer Registry database. Invitation letters (Appendix 
E) and information sheets (Appendix F) were sent to the treating doctor requesting his or her 
permission to contact their patient. The mail-out included a total of 280 patient invitations 
sent to 130 doctors. This occurred on the 2nd of July 2014. Following the doctor’s consent, 
patients were forwarded a study information sheet (Appendix G) and a letter from their 
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doctor (Appendix H) informing them of the details of the study. The first patient mail-out 
occurred on the 9th of July 2014. 
 
Figure 2: Consort diagram outlining responses from phase two of recruitment. Reasons for non-
involvement in the study as reported by individuals who contacted the principal study investigator 
include; Distance – individual commented that the location of the intervention was too far from 
their place of residence, Medication – individual was taking medication that made them ineligible 
to participate, Time – individual was unable to commit to the time requirements of the study, 
Intensity – individual stated that they believed that the intensity of the exercise involved in the study 
would be too great for them. CCQ; Cancer Council Queensland. 
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All individuals who contacted the Principal Investigator were first assessed to determine whether 
they met the eligibility criteria. Those deemed eligible for the study and were willing to participate 
were mailed a copy of the participant information sheet, medical history form, and the general 
physician consent forms. All participants deemed eligible by the study investigators required further 
consent by their medical practitioner prior to the initial testing session. Ethics approval 
(2013000749) was obtained for this project by the Principal Investigator through The University of 
Queensland’s Medical Research Ethics Committee and by the CCQ through the Queensland Public 
Health Act (RD004946); written informed consent was provided by all participants.  
 
3.2.4 Study outline 
Following recruitment, participants were invited to attend an initial face-to-face consultation with 
the Principal Investigator at the Exercise Physiology Research Laboratories within the School of 
Human Movement and Nutrition Sciences at The University of Queensland. During this 
consultation, the pre-testing requirements were discussed with the participant followed by the 
completion of a familiarisation peak cardiorespiratory fitness test. Testing procedures are discussed 
in sections 3.2.5.1 and 3.2.5.3, respectively. Participants performed a baseline testing session prior 
to completing 12 exercise sessions over a 4-week period. All sessions were supervised by an 
Accredited Exercise Physiologist and are described in section 3.2.6. Following the 12 exercise 
sessions, participants completed a final testing session involving the same procedures that were 
included in the baseline testing session. 
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Figure 3: Time-course of study from participant recruitment to endpoint testing 
 
3.2.5 Testing Sessions 
Insulin sensitivity, IGF-I, IGFBP-III concentrations, soft tissue composition, peak heart rate and 
peak cardiorespiratory fitness were assessed at baseline and following the 4-week exercise 
intervention. Testing occurred following a 12-hour fast and required participants to adhere to pre-
testing preparation requirements as outlined in section 3.2.5.1. The start time of the testing session 
differed for each participant, depending on his or her preference and/or availability. Start time was 
the same for baseline and endpoint testing. 
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3.2.5.1 Participant Preparation 
In advance of the testing sessions, participants were required to: 
! Refrain from food and liquid (other than water) for 12 hours prior to the testing session start 
time (first blood draw). 
! Refrain from caffeinated beverages (coffee, tea, selected soft drinks) and alcohol for 24 
hours prior to the testing session.  
! Refrain from vigorous or higher intensity activity for 48 hours prior to the testing session. 
Definitions of ‘vigorous intensity’ and examples of activities that fall within and above this 
category were discussed with the participants to ensure complete understanding.  
! Consume 2-3 cups of water (1 cup = 250 mL) in the 2-3 hours preceding the beginning of 
the testing session. 
Food and liquid intake prior to baseline and endpoint testing were recorded using a 3-day food diary 
(Appendix I). Participants were given a copy of their baseline food diary and asked to replicate it 
prior to the endpoint testing session. In the instance that it was not replicated exactly, participants 
edited the copy of their baseline diary to include any deviations. All participants were asked to 
maintain their pre-intervention level of physical activity outside of the training sessions for the 
duration of the study. Self-reported physical activity was assessed using a validated questionnaire 
(Godin Leisure time Physical Activity Index; Appendix J) (102) at baseline and endpoint testing 
sessions.  
 
Upon arrival for testing at the laboratory, each participant was asked to confirm via a checklist and 
signature that all the pre-exercise criteria had been met. If the above procedures were not met, the 
testing session was rescheduled.  
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Figure 4: Time-course of tests completed during baseline and endpoint testing sessions  
 
3.2.5.2 Primary Endpoints 
Blood Collection Procedures 
Upon arrival for baseline testing, fasting blood (12 mL) was sampled by a qualified phlebotomist 
from an antecubital vein using a 21 G ‘BD Vacutainer Precision Glide’ needle  (Becton, Dickinson 
and Company, New Jersey, USA), ‘BD Vacutainer Cage’ (Becton, Dickinson and Company, New 
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Jersey, USA) and 2 x 6 ml plasma EDTA Vacutainers (Becton, Dickinson and Company, New 
Jersey, USA) and immediately centrifuged for 10 minutes at 500 x g. Plasma was then extracted 
and stored in 5 x 500 µL aliquots in 600 µL Eppendorf collection tubes (Eppendorf, Hamburg, 
Germany) at -80 degrees until analysis.  
 
An OGTT was used to estimate insulin sensitivity. This procedure required a 1 mL fasting blood 
sample followed by a 300 mL drink containing 75 g of sugar (Fronine, Australia). Subsequent 1 mL 
blood samples were collected every 30 minutes over a 2-hour period (30, 60, 90, and 120 minutes). 
Participants were required to rest quietly for the 2-hour sampling period. Blood was sampled from 
an antecubital vein using an indwelling 25 G ‘BD Precision Glide’ needle (Becton, Dickinson and 
Company, New Jersey, USA) and 1 mL syringe (Becton, Dickinson and Company, New Jersey, 
USA). Blood was immediately transferred into a 1 ml plasma EDTA collection tube  (Becton, 
Dickinson and Company, New Jersey, USA) and centrifuged for 10 minutes at 500 x g. Plasma was 
then extracted and stored in 1 x 500 µL aliquot in a 600 µL Eppendorf collection tubes (Eppendorf, 
Hamburg, Germany) tube at -80 degrees until analysis.  
 
Insulin Sensitivity 
Insulin and glucose were analysed using commercially available reagents (R&D Systems, 
Minneapolis, USA) on a Cobas E411 (Roche Diagnostics, Castle Hill, AUS) and RX Daytona Plus 
(Randox, Crumlin, UK) system, respectively. Prior to analysis, samples were thawed and 
centrifuged at 500 x g for 20 seconds.  Standard curves were fitted for insulin and glucose and the 
values for each biomarker calculated accordingly. All sample values recorded were within the range 
of the standards used during analysis. The coefficient of variation (CV) in our laboratory for insulin 
and glucose are 1.48% and 1.19%, respectively. Insulin sensitivity was reported using two 
previously validated methods; the homeostasis model for assessing insulin resistance (HOMA-IR) 
(103) and the Matsuda index for insulin sensitivity (Matsuda ISI) (104). The HOMA-IR and 
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Matsuda ISI indices correlate well with whole body insulin sensitivity measured via the 
hyperinsulinemic-euglycemic clamp (r=0.691 and r=0.732, respectively), the current gold standard 
measurement of insulin sensitivity (104,105).  
 
Insulin-like Growth Factor Axis 
IGF-I and IGFBP-3 concentrations were analysed using commercially available enzyme-linked 
immunosorbent assay (ELISA) kits (R&D Systems, Minneapolis, USA). Prior to analysis, samples 
were thawed and centrifuged at 500 x g for 20 seconds. For analysis of IGF-I and IGFBP-3, 50 µL 
and 100 µL plasma, respectively, were incubated in 96-well antibody-coated plates according to the 
manufacturer’s instructions. Standard curves were fitted for each protein and the values for each 
protein calculated accordingly. All sample values recorded were within the range of the standards 
used during analysis. The CV in our laboratory for IGF-I and IGFBP-3 are 2.25% and 3.71%, 
respectively.  
 
3.2.5.3 Secondary Endpoints 
Peak Cardiorespiratory Fitness (V ̇O2peak)  
The V ̇O2peak test required participants to progressively cycle to volitional fatigue. Expired air was 
analysed for fraction of expired oxygen and fraction of expired carbon dioxide every 15 seconds 
during exercise (ParvoMedics TrueOne 2400, Sandy, USA) from a mixing chamber, while minute 
ventilation was recorded every 15 seconds using a turbine ventilometer (Morgan, Model 096, Kent, 
England). The gas analysers were calibrated immediately prior to testing and validated after each 
test using a certified beta gas mixture (BOC, Brisbane, Australia). The ventilometer was also 
calibrated before and validated after each test using a 3 L syringe (Hans Rudolph series-5530) in 
accordance with the manufacturer’s instructions. Sub-maximal oxygen uptakes were calculated by 
averaging the 30-second readings of fraction of expired oxygen recorded during each minute. 
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V ̇O2peak was recorded as the mean of the two highest 15-second V ̇O2 epochs during the test. This 
is in contrast to V ̇O2max, which requires a plateau in oxygen uptake with an increase in work rate; 
V ̇O2max was not used as a measure of cardiorespiratory fitness for any participant in this 
intervention. The CV in our laboratory for V ̇O2peak is 3.98%. The coefficient of variation refers to 
the variability of duplicate tests on participants from our laboratory; this is repeat V ̇O2peak tests on 
consecutive days under the same conditions. 
 
The cycle test was completed on an electromagnetically braked ‘Excalibur Sport’ cycle ergometer 
(Lode, Groningen, The Netherlands). The testing protocol, modified from that of Balke and Ware 
(106), began with three minutes of rest for respiratory normalisation and was followed by four 
minutes of warm up at a resistance of 50 watts. Thereafter the resistance applied to the cycle 
ergometer increased incrementally by 25 watts each minute. Participants were required to maintain 
a cycling cadence between than 60-70 revolutions per minute throughout the test. The cycle 
ergometer and test protocol were controlled via computer interface linkage (Dell, Texas, USA) and 
software provided with the ergometer (Lode, Groningen, Netherlands). Heart rate, blood pressure, 
and rating of perceived exertion were monitored prior to, and during the test.  Heart rate was 
recorded every minute using a Suunto Ambit2 S heart rate monitor (Suunto Oy, Vantaa, Finland). 
Participant’s peak heart rate (HRpeak) was used to inform training intensities during the intervention. 
This was calculated via the maximum heart rate achieved during the fitness test. Blood pressure was 
monitored every two minutes using a DuraShock Sphygmomanometer (Welch Allyn, New York, 
USA).  Participants were also asked each minute to indicate their rating of perceived exertion 
according to the Borg Scale (107).  The test was terminated when the participant reached volitional 
fatigue or at the discretion of the researchers with consideration for exercise testing termination 
criteria as outlined by the American College of Sports Medicine (100).  
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Body Composition 
Standing height and body mass were measured using a fixed stadiometer (Seca, Birmingham, UK) 
and an analogue scale (Seca, Birmingham, UK), respectively. These measures were used to 
calculate body mass index [body mass in kg divided by height in metres squared (kg/m2)] for each 
participant. 
 
Whole body and regional lean and fat mass for each participant were measured using a ‘Discovery 
W Series’ dual energy x-ray absorptiometry machine (Hologic, Bedford, USA). Participants lay on 
the scanning table for approximately 10 minutes while a scanning arm moved above their body. A 
low-dosage x-ray passed from underneath the table to the scanning arm. Scans were analysed using 
the software (APEX Version 3.3) provided with the machine (Hologic, Bedford, USA) and 
according to the manufacturer’s instructions. The coefficient of variation in our laboratory for 
regional and whole body lean and fat mass is <1.1%.  The CV refers to the variability of duplicate 
scans on participants from our laboratory; this is on-off table repeat scans of older adults. 
 
3.2.6 Exercise Intervention 
The training intervention required participants to exercise three days per week for four weeks 
comprising either; 1) a program of HIE on a cycle ergometer, or 2) a program of MIE on a cycle 
ergometer. Training sessions were conducted on an air- and magnetically-braked cycle ergometer 
(Wattbike ProTM, Wattbike Ltd., Nottingham, England) in the Exercise Physiology Research 
Laboratories within the School of Human Movement and Nutrition Sciences at The University of 
Queensland. Exercise sessions were scheduled on non-consecutive days to allow for adequate 
recovery and all sessions were supervised with a ratio no greater than one Exercise Physiologist for 
every three participants. 
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3.2.6.1 High Intensity Exercise Group 
The high intensity exercise (HIE) group followed the same protocol as outlined previously by 
Tjonna et al. (26). A complete time-course of the HIE group is shown in Figure 5. HRpeak ranges 
used for participants were calculated as a percentage of the HRpeak recorded during the aerobic 
fitness test as described in section 3.2.5.3.  The HIE group session began with a cycling warm-up at 
50-70% of HRpeak for 10 minutes followed by 4 x 4 minute bouts of cycling at an intensity 
corresponding to 85-95% of the participants HRpeak. Each 4 min interval was interspersed with three 
minutes of active recovery, cycling at 50-70% HRpeak. The session ended with a three minute cool 
down, cycling at an intensity of 50-70% HRpeak. The total duration of each HIE session was 38 
minutes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Time-course of high intensity exercise session 
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Power output during the session was self-selected as a function of cadence and workload, to allow 
participants to maintain a heart rate within the prescribed intensity range. Rating of perceived 
exertion was recorded at the end of each interval using the Borg scale (107). If a participant reached 
a Borg rating of ‘20’, the exercise session was terminated to minimise the potential of any adverse 
events related to the HIE.  
 
3.2.6.2 Moderate Intensity Exercise Group 
Participants assigned to the moderate intensity exercise (MIE) group cycled continuously at 50-70% 
HRpeak for 50 minutes. This duration (150 minutes per week) and intensity is consistent with the 
current exercise oncology guidelines (43). Rating of perceived exertion was recorded at 10 minute 
intervals during the session using the Borg scale (107). If a participant reached a Borg rating of 
‘15’, the power output on the cycle ergometer was reduced to ensure a moderate intensity was 
maintained. The total duration of each MIE session was 50 minutes. 
 
3.2.6.3 Safety and Attendance 
Upon arriving at the laboratories for the exercise training session, participants had their baseline 
heart rate and blood pressure measured using a Suunto ‘Ambit2S’ heart rate wrist monitor and chest 
strap (Suunto, Finland) and DuraShock Sphygmomanometer (Welch Allyn, New York, USA), 
respectively. The heart rate monitor and chest strap were kept on the participant for the duration of 
the session. These values were recorded and used as a resting threshold that participants needed to 
return to before they were discharged after their exercise session. An Accredited Exercise 
Physiologist (Andrew Sax) supervised all sessions during the intervention. Heart rate ranges were 
continuously monitored during each session to ensure participants were conforming to their 
prescribed heart rate intensities. If participants were not meeting their prescribed heart rate 
intensities they were encouraged to alter their power output (via cadence or workload) to meet this 
criteria.  
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Participants were asked to report any adverse events experienced during the exercise sessions to the 
Exercise Physiologist, and these were recorded over the duration of the study. Attendance during 
the intervention was measured via total number of sessions attended (out of 12 possible sessions).  
 
3.2.6.4 Statistical analysis 
To achieve 80% power at an alpha level of 0.05 (two-tailed), three participants per group were 
required to demonstrate a 1 standard deviation (SD) difference in the primary outcome (insulin 
sensitivity) between groups at the end of the 4-week intervention. Sample size calculations were 
based on the homeostasis model of assessment for insulin sensitivity data from Tjonna et al. (26) 
using G*Power version 3.1 software (G*Power Software, University of Düsseldorf, Germany). To 
account for 25% attrition, which has previously been reported from our laboratory, a minimum of 
five participants were needed to be randomised to each group. 
 
Data was analysed using the SPSS statistical software package (version 20.0, SPSS, Inc., Chicago, 
IL). Data were assessed for normality using the Kolmogorov-Smirnov test. Where data were not 
normally distributed (i.e. fasting insulin, fasting glucose and the HOMA-IR), log-transformations 
were performed and rechecked for normality prior to analysis. In the instances that log transformed 
data were not normally distributed (V ̇O2peak), non-parametric analyses were used on the raw 
(untransformed) data. Analyses included standard descriptive statistics, t tests, analysis of 
covariance, and Wilcoxon-signed rank tests where appropriate. Statistical analyses were based on 
an intention-to-treat approach, however as the exercise session attendance was 100% this was 
synonymous with per protocol analysis. Missing data points were not replaced. Analyses also 
included Pearson or Spearman correlation coefficients, as appropriate, to examine the association 
between insulin sensitivity, IGF axis, body composition and cardiorespiratory fitness. Partial 
correlations controlling for age, sex, cancer stage, cancer location, cancer treatment, time since 
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diagnosis and baseline biological variables were performed. Analysis of covariance adjusted for 
baseline values was used for the primary and secondary endpoints. All tests were two-tailed and an 
alpha level of 0.05 was applied as the criterion for statistical significance. Results are given as the 
mean ± SD unless otherwise stated.   
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3.3 Results 
3.3.1 Participant characteristics  
A consort diagram of the participant flow through the intervention is detailed in Figure 6. Baseline 
characteristics of the 29 participants are presented in Table 1a. Participants in the HIE and MIE 
groups were aged 33-84 and 44-82 years, respectively. At baseline, there were no significant 
differences between groups for participant characteristics (i.e. age, sex, BMI, cancer history, cancer 
stage, cancer treatment; Table 1a) or any of the outcome measures (Table 1b).  
 
3.3.2 Attendance, safety and adherence   
Of the total 348 exercise sessions, attendance was 100%. There were no adverse events in response 
to the exercise sessions reported or observed during the intervention. The total combined time 
participants’ spent exercising during the intervention was approximately 260 hours. A total of 228 
sessions were completed by the HIE group during the intervention; this equates to 912 individual 
high-intensity intervals. Over the course of these intervals, the average time it took for participants 
to reach their prescribed HRpeak (85% - 95% HRpeak) intensity range was 38±39 seconds.  Thus, 
in each of the training sessions, participants in the HIE group spent approximately 14 minutes in the 
target training zone, equating to a total of 168 minutes per participant over the duration of the entire 
training intervention. 
 
3.3.3 Physical activity outside intervention    
There were no significant between-group differences in the amount of physical activity completed 
by participants outside of the intervention at baseline (p = 0.542) or at the end of the 4-week 
intervention (p = 0.946). Physical activity completed by participants in either group outside the 
intervention did not change from baseline to the end of the study (HIE, p = 0.879; MIE, p = 0.878).  
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Figure 6: CONSRT diagram outlining participant flow through the intervention. 
 
  
Endpoint!Testing!
Intervention!
Baseline!Testing!
Allocation!
Enrollment! Randomised!to!trial!(n=29)!
Randomised!to!HIE!group!(n=19)!
!
Blood'Analysis'
Fasting(indices((n=19)(
Mastuda(Index((n=12)(
120min(glucose((n=16)(Cardiorespiratory!Fitness!(n=17)!Body!Composition!(n=19)!!
Completed!internvention!(n=19)!
Blood'Analysis'
Fasting(Indices((n=19)(
Matsuda(Index((n=12)(
120min(glucose((n=16)(Cardiorespiratory!Fitness!(n=17)!Body!Composition!(n=19)!
Randomised!to!MIE!group!(n=10)!
Blood'Analysis'
Fasting(indices((n=10)(
Mastuda(Index((n=4)(
120min(glucose((n=4)(Cardiorespiratory!Fitness!(n=8)!Body!Composition!(n=10)!
Completed!intervention!(n=10)!
Blood'Analysis'
Fasting(Indicies((n=10)(
Matsuda(Index((n=4)(
120min(glucose((n=4)(Cardiorespiratory!Qitness!(n=8)!Body!Composition!(n=10)!
 47 
Table 1a: Baseline characteristics of participants randomised to the HIE and MIE groups. 
 
 
Values reported as [n (%)] unless otherwise specified, ‡ Values reported as mean ± standard 
deviation, # Values reported as median (inter-quartile range), † Chi squared analysis used to 
determine significance between groups, HIE: High Intensity Exercise, MIE: Moderate Intensity 
Exercise, BMI: Body Mass Index. Physical activity level reported in Godin Minutes (102). 
 
 
 
 
 
 HIE (n=19) 
MIE 
(n=10) 
p value 
Age (years) ‡ 60.9 ± 13.2 61.2 ± 10.6 0.959 
Male 13 (68.4) 4 (40.0) 0.140 
Body mass (kg) ‡ 78.53 ± 16.43 77.96 ± 19.51 0.564 
BMI (kg/m2) ‡ 26.17 ± 4.61 27.03 ± 4.03 0.625 
Physical activity 21.00 (23.00) 30.50 (29.80) 0.542 
Cancer History    
Colon cancer † 17 (89.5) 9 (90.0) 0.965 
Rectal cancer † 2 (10.5) 1 (10.0) 0.965 
Time since diagnosis 
(years) # 2.0 (7.0)  3.3 (7.1)  0.353 
Time since final 
treatment (years) # 2.0 (7.5)  2.3 (3.2)  0.982 
Cancer Stage     
Stage A † 3 (15.8) 4 (40.0) 0.148 
Stage B † 10 (52.6) 3 (30.0) 0.244 
Stage C † 4 (21.1) 3 (30.0) 0.593 
Stage D † 2 (10.5) 0 (0.0) 0.288 
Cancer Treatment     
Surgery † 7 (36.8) 4 (40.0) 0.868 
Surgery & 
chemotherapy † 8 (42.1) 3 (30.0) 0.713 
Surgery & radiation † 1 (5.3) 0 (0.0) 0.460 
Surgery, 
chemotherapy & 
radiation † 
2 (10.5) 3 (30.0) 0.187 
Chemotherapy & 
radiation † 1 (5.3) 0 (0.0) 0.460 
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Table 1b: Baseline testing data of participants randomised to the HIE and MIE groups. 
 
Values reported as mean ± standard deviation unless otherwise stated,‡ Values reported as median 
(inter-quartile range), HIE: High Intensity Exercise, MIE: Moderate Intensity Exercise, IGF-I: 
Insulin-like Growth Factor I, IGFBP-III: Insulin-like Growth Factor Binding Protein III, HOMA-
IR: Homeostatic Model Assessment - Insulin Resistance, V ̇O2peak: Peak Volume of Oxygen 
Consumed.  
 
 
 
 HIE (n=19) 
MIE 
(n=10) 
p value 
Insulin Sensitivity     
Fasting Glucose 
(mmol/L) ‡ 
5.6 (1.0) 5.7 (0.9) 0.821 
Fasting Insulin 
(pmol/L) ‡ 
72.4 (56.6) 57.9 (36.9) 0.727 
HOMA-IR ‡ 2.7 (1.6) 2.1 (1.4) 0.705 
 (n=12) (n=4)  
Matsuda Index  5.1 ± 3.3 5.0 ± 1.3 0.572 
 (n=16) (n=4)  
120 min Glucose 
(mmol/L) 
6.9 ± 1.9 5.8 ± 1.2 0.284 
    
IGF Axis (n=19) (n=10)  
IGF-I (ng/mL) 74.6 ± 21.1 75.3 ± 22.8 0.899 
IGFBP- III  (ng/mL) 2354.6 ± 705.1 2465.0 ± 656.5 0.685 
    
Body Composition (n=19) (n=10)  
Lean Mass (kg)  45.9 ± 10.2 41.9 ± 13.8 0.371 
Fat Mass (kg) 24.5 ± 8.2 27.9 ± 10.3 0.326 
Body Fat (%) 33.4 ± 6.9 39.0 ± 8.1 0.064 
    
Cardiorespiratory 
Fitness 
(n=17) (n=8)  
Relative V ̇O2peak 
(ml.kg-1.min-1) ‡ 
23.3 (6.7) 20.9 (5.2) 0.120 
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3.3.4 Insulin sensitivity    
There were no significant differences between groups for fasting glucose (p = 0.626), fasting insulin 
(p = 0.583), HOMA-IR (p = 0.367), Matsuda Index (p = 0.490), or 120 min glucose (p = 0.372) at 
baseline. Changes in all measures of insulin sensitivity over four weeks did not significantly differ 
between the groups (Table 2). Furthermore, no significant differences were found between groups 
for fasting glucose (p = 0.494), fasting insulin (p = 0.356), HOMA-IR (p = 0.327), Matsuda Index 
(p = 0.870), or 120 min glucose (p = 0.488) at the end of the 4-week intervention.  
 
There was a significant within-group change in the 120 min blood glucose concentration of -7.1% 
in the HIE (p = 0.037) but not MIE (+0.8%, p = 0.866) group (Table 3). Within-group changes in 
the HIE and MIE groups for fasting glucose were +2.2% (p = 0.863) and -2.1% (p = 0.598), for 
fasting insulin -10.6% (p = 0.179) and -16.9% (p = 0.064), for HOMA-IR -13.7% (p = 0.174) and -
15.1% (p = 0.107), and for Matsuda Index +13.8% (p = 0.142) and +0.8% (p = 0.933), respectively.  
 
Aggregated or training-group specific changes in insulin sensitivity were not significantly (p > 
0.05) correlated with changes in fat mass, lean mass, or body fat percentage (Table 4).  Between 
group differences in insulin sensitivity were also not significantly different after controlling for age, 
sex, cancer stage, cancer location, cancer treatment, time since diagnosis or baseline biological 
variables.  
 
Pre- and post-intervention HOMA-IR levels of each participant are shown in Figure 7.  Matsuda 
Index could not be calculated for 13 participants (HIE n = 7, MIE n = 6) and 120 min glucose for 9 
participants (HIE n = 3, MIE n = 6) due to an inability to obtain the blood samples required to 
complete the respective analyses.  
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Table 2: Insulin sensitivity and IGF axis values and change over four weeks  
 MIE: Baseline HIE: Baseline MIE: Endpoint HIE: Endpoint Difference between groups in mean change (95% CI) p value  
Insulin Sensitivity  (n=10) (n=19) (n=10) (n=19)   
Fasting Glucose 
(mmol/L) ‡ 
5.7 (0.9) 5.6 (1.0) 5.6 (0.9) 5.7 (0.8) -0.1 (-0.6-0.3) 0.511 
Fasting Insulin 
(pmol/L) ‡ 
57.9 (36.9) 72.4 (56.6) 48.1 (59.9) 64.7 (26.2) -5.5 (-23.5-12.5) 0.536 
HOMA-IR ‡ 2.1 (1.4) 2.7 (1.6) 1.7 (1.9) 2.3 (1.3) -0.2 (-0.9-0.5) 0.518 
 (n=4) (n=12) (n=4) (n=12)   
Matsuda Index  5.0 ± 1.3 5.1 ± 3.3 5.1 ± 1.6 5.9 ± 3.9 -0.6 (-2.2-1.1) 0.482 
 (n=4) (n=16) (n=4) (n=16)   
120 min Glucose 
(mmol/L) 
5.8 ± 1.2 6.9 ± 1.9 5.9 ± 0.6 6.4 ± 1.5 0.2 (-0.6-1.0) 0.563 
IGF Axis (n=10) (n=19) (n=10) (n=19)   
IGF-I (ng/mL) 75.3 ± 22.8 74.6 ± 21.1 68.7 ± 18.7 79.9 ± 22.1 -11.8 (-26.5-2.9) 0.112 
IGFBP-III (ng/mL) 2465.0 ± 656.5 2354.6 ± 705.1 2539.6 ± 674.4 2395.8 ± 802.3 68.3 (-423.1-559.7) 0.777 
Values reported as mean ± standard deviation unless otherwise stated,‡ Values reported as median (inter-quartile range), CI: Confidence Interval, HIE: 
High Intensity Exercise, MIE: Moderate Intensity Exercise, IGF-I: Insulin-like Growth Factor I, IGFBP- III: Insulin-like Growth Factor Binding 
Protein III, HOMA-IR: Homeostatic Model Assessment - Insulin Resistance.  
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Table 3: Within-group comparisons for insulin sensitivity and IGF axis values over four weeks 
 MIE: Baseline MIE: Endpoint p value  HIE: Baseline HIE: Endpoint p value  
Insulin Sensitivity  (n=10) (n=10)  (n=19) (n=19)  
Fasting Glucose 
(mmol/L) ‡ 
5.7 (0.9) 5.6 (0.9) 0.598 5.6 (1.0) 5.7 (0.8) 0.863  
Fasting Insulin 
(pmol/L) ‡ 
57.9 (36.9) 48.1 (59.9) 0.064 72.4 (56.6) 64.7 (26.2) 0.179 
HOMA-IR ‡ 2.1 (1.4) 1.7 (1.9) 0.107 2.7 (1.6) 2.3 (1.3) 0.174 
 (n=4) (n=4)  (n=12) (n=12)  
Matsuda Index  5.0 ± 1.3 5.1 ± 1.6 0.933 5.1 ± 3.3 5.9 ± 3.9 0.142  
 (n=4) (n=4)  (n=16) (n=16)  
120 min Glucose 
(mmol/L) 
5.8 ± 1.1 5.9 ± 0.6 0.866 6.9 ± 1.9 6.4 ± 1.5 0.037* 
IGF Axis (n=10) (n=10)  (n=19) (n=19)  
IGF-I (ng/mL) 75.3 ± 22.8 68.7 ± 18.7 0.301 74.6 ± 21.1 79.9 ± 22.1 0.299  
IGFBP- III (ng/mL) 2465.0 ± 656.5 2539.6 ± 674.4 0.642 2354.6 ± 705.1 2395.8 ± 802.3 0.800  
 
Values reported as mean ± standard deviation unless otherwise stated, ‡ Values reported as median (inter-quartile range), * p ≤ 0.05, HIE: High 
Intensity Exercise, MIE: Moderate Intensity Exercise, IGF-I: Insulin-like Growth Factor I, IGFBP- III: Insulin-like Growth Factor Binding Protein III, 
HOMA-IR: Homeostatic Model Assessment - Insulin Resistance. 
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Table 4: Relationships among absolute changes in insulin sensitivity, IGF axis and body composition over four weeks 
 
Δ IGF-I 
(ng/mL) 
Δ IGFBP- 
III (ng/mL) 
Δ Fasting 
Glucose 
(mmol/L) 
Δ Fasting 
Insulin 
(pmol/L) 
Δ HOMA-
IR 
Δ Matsuda 
Index ‡ 
Δ 120min 
Glucose 
(mmol/L) 
Δ Lean 
Mass (kg) 
Δ Body Fat 
%  
Δ IGF-I (ng/mL) 1         
Δ IGFBP-III 
(ng/mL) 
0.472    
(0.010)** 
1        
Δ Fasting Glucose 
(mmol/L) 
0.445    
(0.016)* 
-0.016 
(0.933) 
1       
Δ Fasting Insulin 
(pmol/L) 
0.306    
(0.106) 
0.210 
(0.274) 
0.288 
(0.130) 
1      
Δ HOMA-IR 0.352    
(0.061) 
0.226 
(0.239) 
0.480 
(0.008)** 
0.961 
(0.000)** 
1     
Δ Matsuda Index ‡ -0.446   
(0.029)* 
-0.137 
(0.522) 
-0.289 
(0.171) 
-0.580 
(0.003)** 
-0.606 
(0.002)** 
1    
Δ 120min Glucose 
(mmol/L) 
0.071    
(0.766) 
0.401 
(0.079) 
-0.080 
(0.738) 
0.052 
(0.829) 
0.100 
(0.675) 
-0.059 
(0.806) 
1   
Δ Lean Mass (kg) 0.107    
(0.582) 
-0.113 
(0.561) 
0.346 
(0.066) 
0.096 
(0.620) 
0.162 
(0.401) 
0.237 
(0.266) 
0.011   
(0.964) 
1  
Δ Body Fat % -0.036   
(0.851) 
0.092 
(0.637) 
-0.002 
(0.993) 
-0.024 
(0.900) 
-0.039 
(0.841) 
-0.329 
(0.116) 
-0.203   
(0.392) 
-0.791 
(0.000)** 
1 
Δ Fat mass (kg) -0.103   
(0.594) 
0.191 
(0.320) 
-0.046 
(0.812) 
-0.075 
(0.699) 
-0.082 
(0.671) 
-0.297 
(0.158) 
0.007   
(0.977) 
-0.644 
(0.000)** 
0.891 
(0.000)** 
Values reported as  [Correlation (p value)], * p ≤ 0.05, ** p ≤ 0.01, ‡ Spearman correlation used for non-parametric data, IGF-I: Insulin-like Growth 
Factor I, IGFBP-III: Insulin-like Growth Factor Binding Protein III, HOMA-IR: Homeostatic Model for the Assessment of Insulin Resistance, 
V ̇O2peak: Peak Volume of Oxygen Consumed. 
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3.3.5 Insulin-like growth factor axis 
There were no significant between-group differences in IGF-I (p = 0.717) or IGFBP-III (p = 0.292) 
at baseline. Changes in IGF-I and IGFBP-III over 4-weeks did not significantly differ between the 
groups (Table 2). There were also no significant between-group differences for IGF-I (p = 0.183) 
and IGFBP-III (p = 0.633) following the 4-week intervention. Pre- and post-intervention IGF-I and 
IGFBP-III levels of each participant are shown in Figure 7. There were no significant within-group 
changes for IGF-I (HIE +6.5%, p = 0.299; MIE -8.9%, p = 0.301) or IGFBP-III (HIE +1.7%, p = 
0.800; MIE +3.0%, p = 0.642) from baseline to endpoint testing (Table 3). Aggregated or training-
group specific changes in the IGF axis were not significantly (p ≥ 0.05) correlated with changes in 
fat mass, lean mass, or body fat percentage (Table 4).  Between group differences for the IGF-I and 
IGFBP-III were also not significantly different when controlling for age, sex, cancer stage, cancer 
location, cancer treatment, time since diagnosis or baseline biological variables.  
 
When data was subdivided by time since last treatment (≤5 years >5 years), no significant within-
group differences were found for IGF-I (≤5 years, MIE, p = 0.288; >5 years, MIE, p = 0.827; ≤5 
years, HIE, p = 0.205; >5 years, HIE, p = 0.325) or IGFBP-III (≤5 years, MIE, p = 0.851; >5 years, 
MIE, p = 0.717; ≤5 years, HIE, p = 0.205; >5 years, HIE, p = 0.126). The same stratification 
showed no significant between-group differences at baseline (≤5 years, IGF-I, p = 0.976; >5 years, 
IGF-I, p = 0.328; ≤5 years, IGFBP-III, p = 0.689; >5 years, IGFBP-III, p = 0.063), or endpoint (≤5 
years, IGF-I, p = 0.678; >5 years, IGF-I, p = 0.358; ≤5 years, IGFBP-III, p = 0.817; >5 years, 
IGFBP-III, p = 0.304).  
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Figure 7: Individual participant pre- to post-intervention IGF-1 (top), IGFBP-3 (middle) and HOMA-IR 
(bottom) values. The dotted lines represent the mean value. IGF-I: Insulin-like Growth Factor I. IGFBP- III: 
Insulin-like Growth Factor Binding Protein III. HOMA-IR: Homeostatic Model for the Assessment of Insulin 
Resistance. HIE: High Intensity Exercise. MIE: Moderate Intensity Exercise.  
Endpoint Endpoint 
Endpoint Endpoint 
Endpoint Endpoint 
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3.3.6 Cardiorespiratory fitness  
There were no significant between- group differences for V ̇O2peak (p = 0.140) at baseline. Changes 
in V ̇O2peak did not significantly differ between groups (Table 5). There were no significant 
between-group differences for V ̇O2peak (p = 0.124) following the 4-week intervention. 
 
There were significant within-group differences in absolute V ̇O2peak values for both the HIE 
(23.0%, p = 0.013) and MIE (1.7%, p = 0.025) groups over the 4-week intervention (Table 6). 
Changes in V ̇O2peak were not significantly correlated (p > 0.05) with insulin sensitivity, the IGF 
axis or body composition (Table 4). Pre- and post-intervention V ̇O2peak levels of each participant 
are shown in Figure 9. 
 
Relative V ̇O2peak data were unable to be obtained for four participants (HIE n = 2, MIE n = 2); two 
participants (MIE) experienced nausea and vomiting in response to the OGTT glucose drink and 
had their testing session terminated prior to the cardiorespiratory fitness test. One participant (HIE) 
was not comfortable wearing the mouthpiece required to measure relative V ̇O2peak data. A 
technical error was experienced during the endpoint cardiorespiratory fitness test of one participant 
(HIE) and their data had to be excluded. 
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Table 5: Body composition and cardiorespiratory fitness values and change over four weeks  
 MIE: Baseline HIE: Baseline MIE: Endpoint HIE: Endpoint Difference between groups in mean change (95% CI) p value  
Body Composition (n=10) (n=19) (n=10) (n=19)   
Lean Mass (kg)  41.9 ± 13.8 45.9 ± 10.2 42.5 ± 14.4 46.8 ± 10.5 -0.0 (-0.6-0.6) 0.975 
Fat Mass (kg) 27.9 ± 10.3 24.5 ± 8.2 27.6 ± 10.5 23.7 ± 8.2 0.4 (-0.3-1.1) 0.227 
Body Fat (%) 39.0 ± 8.1 33.4 ± 6.9 38.3 ± 8.7 32.3 ± 7.4 0.1 (-0.8-1.1) 0.767 
Cardiorespiratory 
Fitness 
(n=8) (n=17) (n=8) (n=17)   
Relative V ̇O2peak 
(ml.kg-1..min-1) ‡ 
20.9 (5.2) 23.3 (6.7) 21.3 (8.5) 28.6 (10.7) -1.5 (-4.9-1.9) 0.361 
Values reported as [mean ± standard deviation] unless otherwise stated. ‡ Values reported as median (inter-quartile range). CI: Confidence Interval, 
HIE: High Intensity Exercise. MIE: Moderate Intensity Exercise. V ̇O2peak: Peak Volume of Oxygen Consumed. 
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Table 6: Within-group comparisons in body composition and cardiorespiratory fitness over four weeks 
 MIE: Baseline MIE: Endpoint p value  HIE: Baseline HIE: Endpoint p value  
Body Composition (n=10) (n=10)  (n=19) (n=19)  
Lean Mass (kg)  41.9 ± 13.8 42.5 ± 14.4 0.071 45.9 ± 10.2 46.8 ± 10.5 0.001** 
Fat Mass (kg) 27.9 ± 10.3 27.6 ± 10.5 0.263 24.5 ± 8.2 23.7 ± 8.2 0.001** 
Body Fat (%) 39.0 ± 8.1 38.3 ± 8.7 0.132 33.4 ± 6.9 32.3 ± 7.4 0.001** 
Cardiorespiratory 
Fitness (n=8) (n=8)  (n=17) (n=17)  
Relative V ̇O2peak 
(ml.kg-1.min-1) ‡ 20.9 (5.2) 21.3 (8.5) 0.025* 23.3 (6.7) 28.6 (10.7) 0.013* 
Values reported as mean ± standard deviation unless otherwise stated. * p ≤ 0.05. ** p ≤ 0.001. ‡ Values reported as median (inter-quartile range). HIE: 
High Intensity Exercise. MIE: Moderate Intensity Exercise. V ̇O2peak: Peak Volume of Oxygen Consumed.
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Figure 8: Pre and post-intervention mean values for A) relative VO2 peak; B) whole body fat percentage; 
C) whole body fat mass; D) and whole body lean mass. Dark grey denotes baseline values; light grey 
denotes endpoint values. Error bars denote SD. * p ≤ 0.05 versus baseline. ** p ≤ 0.001 versus baseline. 
VO2peak: Peak Volume of Oxygen Consumed. HIE: High Intensity Exercise. MIE: Moderate Intensity 
Exercise. 
* 
* ** 
** 
** 
HIE 
HIE 
MIE 
MIE 
A B 
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Figure 9: Individual participant pre- to post-intervention V ̇O2peak (top), whole body lean mass 
(middle) and whole body fat mass (bottom) values. The dotted lines represent the mean value. 
V ̇O2peak: Peak Volume of Oxygen Consumed. HIE: High Intensity Exercise, MIE: Moderate 
Intensity Exercise.  
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3.3.7 Body composition    
There were no significant between-group differences for whole body lean mass (p = 0.371), fat 
mass (p = 0.326), and fat percentage (p = 0.064) at baseline. There were no significant between-
group differences for lean mass (p = 0.370), fat mass (p = 0.277), and body fat percentage (p = 
0.061) following the 4-week intervention (Table 5).  There were significant within-group changes 
for the HIE but not MIE group in lean mass (HIE +1.8%, p ≤ 0.001; MIE +1.6%, p = 0.071), fat 
mass (HIE -3.3%, p ≤ 0.001; MIE -1.4%, p = 0.263), and body fat percentage (HIE -3.3%, p ≤ 0.001 
MIE +1.7%, p = 0.132) from baseline to endpoint testing (Table 6) (Figure 8). Pre- and post-
intervention lean mass and fat mass levels of each participant are shown in Figure 9. Changes in 
each measure of body composition were not significantly correlated with changes in insulin 
sensitivity or the IGF axis (Table 4).  
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3.4 Discussion 
The primary aim of the present study was to examine the influence of exercise intensity on insulin 
sensitivity and the IGF axis in colorectal cancer survivors.  In addition, changes in body 
composition and cardiovascular fitness were assessed in response to the two different training 
intensities. Following the 4-week intervention, there were no significant between-group differences 
for any measure at the end of the 4-week intervention. There were significant improvements in 120 
min glucose concentrations in the HIE group only following the intervention. No significant within-
group changes were found for other measures of insulin sensitivity, IGF-I, or IGFBP-III. Significant 
improvements were found for VO2peak in both the HIE and MIE groups, and for lean mass, fat 
mass, and fat percentage in the HIE group only.  
 
Insulin Sensitivity 
It was hypothesised that HIE training would result in greater improvements in measures of insulin 
sensitivity compared to MIE training due to the higher recruitment and activation of neuromuscular 
motor units associated with HIE (108). However, apart from lower 120 min glucose concentrations 
for the HIE group following the intervention, there were no other significant changes in insulin 
sensitivity as measured by fasting glucose, fasting insulin, HOMA-IR or Matsuda index in response 
to training for either the HIE or MIE group.  
 
Blood was sampled in the present study approximately 170-hours (1 week) after the final exercise 
session. Acute improvements in insulin sensitivity are known to diminish after 48-hours and this 
may explain why no significant changes in fasting glucose, insulin, HOMA-IR or Matsuda index 
were reported following the intervention (109). Despite this, exercise has been linked to chronic 
improvements in insulin sensitivity that extend beyond this 48-hour window (109), and this 
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suggests that the non-significant changes reported in this study may be due to factors other than the 
timing of sampling; these will be discussed in the following sections.  
 
Currently, only one study has investigated changes in insulin sensitivity following an exercise 
intervention in colorectal cancer survivors (n = 17) (110). The study by Lee et al. (110) involved 12 
weeks of home-based moderate intensity exercise such as hiking, swimming and stationary cycling 
equating to 27 MET-hours of exercise per week. Following the intervention, significant reductions 
in fasting insulin (p = 0.006) and HOMA-IR (p = 0.017) were observed, representing an 
improvement in whole body insulin sensitivity (104). Baseline fasting insulin and HOMA-IR in the 
study by Lee at al. (110) were 46.3 pmol/L (SD = 31.8) and 1.7 (SD = 1.2), respectively; in 
comparison, baseline fasting insulin and HOMA-IR for participants in the HIE group in the present 
study were 72.4 pmol/L (SD = 56.6) and 2.1 (SD = 1.6) respectively. This indicates that participants 
in our study had poorer insulin sensitivity at baseline than the colorectal cancer survivors examined 
by Lee et al. (110). The disparity in baseline insulin sensitivity across studies may, in part, be 
explained by differences in average body fat percentage, with participants from the study by Lee et 
al. (110) reporting 26.6% body fat compared to 33.4% within the present study. The method used to 
determine body composition in the study by Lee et al. (110) was not reported. Compared to people 
with high baseline insulin sensitivity, those with poor baseline insulin sensitivity have been found to 
experience greater improvements in insulin sensitivity following a 16-week exercise intervention 
(111). In light of this and the findings from Lee et al. (110), it was reasonable to expect that there 
would be significant improvements in fasting insulin and HOMA-IR following the current 
intervention. The absence of improvement in fasting insulin and HOMA-IR in response to the 
current intervention suggests that factors other than the participants’ baseline values need to be 
explored. Factors such as the duration of the intervention and the intensity of the training program 
are discussed below.  
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Mean fasting glucose for participants in the present HIE group at baseline was 5.6 mmol/L; this 
falls within the limits defined by the American Diabetes Association for ‘pre-diabetes’ (5.6-6.9 
mmol/L) (112). Physical activity has consistently been shown to reduce fasting glucose in both pre-
diabetic and diabetic populations (113). Apart from the present trial, the only other study to have 
measured changes in fasting glucose in response to an exercise intervention in colorectal cancer 
survivors also found no significant change in fasting insulin following the intervention (110). A 
plausible explanation for the non-significant changes in fasting glucose following in the current 
intervention may be related to the measure itself. It has been reported that simple indices of insulin 
sensitivity, based on fasting plasma measures alone, cannot always reliably estimate insulin 
resistance (105). This is due to a biological variance (day-to-day changes under the same 
conditions) that exists for fasting measures of insulin sensitivity, which becomes more pronounced 
in persons who are pre-diabetic, such as those in the present study (105). Specifically, when 
comparing HOMA-IR measures on separate occasions, Jayagopal et al. (114) reported greater intra-
individual variation for those with type 2 diabetes (CV = 1.05) compared to normoglycemic 
controls (CV = 0.15) (p = 0.001). Indeed, this biological variability for fasting indices may also 
explain, at least in part, the non-significant changes in fasting insulin and HOMA-IR reported in the 
present study. More reliable measures of assessing insulin sensitivity such as the OGTT and the 
euglycemic hyperinsulinemic clamp are available; the strengths and limitations of these are 
discussed below.   
 
An OGTT was utilised in the present study in order to account for the limitations associated with 
simpler measures of insulin sensitivity (e.g. fasting glucose, fasting insulin, HOMA-IR) that were 
mentioned above. The Matsuda index and 120 min glucose indices were extrapolated from the 
OGTT to determine insulin sensitivity. To date, the Matsuda index and measures of 120 min 
glucose have not been utilised in exercise interventions for any population of cancer survivors, 
limiting the comparisons that can be made between the present findings and those of others. Whilst 
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missing data due to difficulties obtaining sufficient quantities of blood at various time points limited 
our ability to interpret findings from the OGTT-derived Matsuda index and 120 min (Table 1b) 
glucose measures, significant improvements were reported in the HIE group for the 120 min 
glucose, but not Matsuda index following the intervention. The 120 min glucose measure used in 
the present study has previously been reported to correlate well with insulin sensitivity measured 
via the euglycemic hyperinsulinemic clamp (115). Based on the 120min glucose measure alone, this 
suggests that participants in the HIE group improved their insulin sensitivity following the 4-week 
intervention. However, given that there were no changes in any other measure of insulin sensitivity, 
it is not possible to conclude with certainty that improvements in glucose control occurred in 
response to the HIE intervention. . 
 
The Matsuda index is currently considered the best alternative to the euglycemic hyperinsulinemic 
clamp with a Pearson’s correlation of 0.732 (p = 0.0001) (116). However, the Matsuda index is 
considered to be more precise in persons with normal glucose tolerance (r = 0.73, p = 0.0001) 
compared to those with impaired glucose tolerance (r = 0.66, p = 0.0001) (116), such as the 
participants in the present study. This reduced reliability may, in part at least, explain the non-
significant findings in insulin sensitivity in the present study.  
 
The intensity and/or duration of the exercise programs used in the present study may have 
contributed to the lack of improvement (apart from 120 min glucose) observed across the insulin 
sensitivity measures. The 4-week duration of the intervention was chosen in light of previous 
research that reported significant improvements in markers of insulin sensitivity after only 2-weeks 
(6 sessions) of high intensity interval training (18,117). In these trials, pre-intervention fasting 
glucose concentrations for obese men (n = 10) (18) and sedentary but otherwise healthy adults (n = 
12) (117) were 2% and 21% ‘better’, respectively, than the values for participants in the present 
study. As mentioned previously, individuals with lower baseline insulin sensitivity are likely to 
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improve to a greater degree following an exercise intervention when compared to those with poor 
baseline insulin sensitivity (111). Given that baseline insulin sensitivity measures observed in the 
current trial were ‘worse’ than the values reported by Whyte et al. (18) and Richards et al. (117), we 
expected to see significant changes following the intervention. Reasons for differences in the 
findings between the present study and those of Whyte et al. (18) and Richards et al. (117) may 
therefore be related to the intensity of the training protocol utilised by these trials. Both of these 
previous exercise protocols involved a series of 4-7 ‘all out’ cycle ergometer sprints for a total 
duration of 30 seconds each. While the specific exercise intensity was not reported in these trials, 
given that it was repeated ‘all out’ efforts, it is reasonable to assume that the exercise intensity was 
above the 85-95% HRpeak achieved by those in the present HIE group (118). 
 
In comparison to the 27 MET-hours of exercise per week completed by participants in the study by 
Lee et al (110), participants in the current study completed 19 and 17 MET-hours per week for the 
HIE and MIE group, respectively. This suggests that, at least for colorectal cancer survivors, a 
greater quantity of exercise is required for significant changes in insulin sensitivity to occur. 
 
Improvements in insulin sensitivity following HIE have been associated with a larger increase in 
skeletal muscle blood flow compared to MIE (118). To achieve the power outputs required in the 
studies by Whyte et al. (18) and Richards et al. (117), the exercise intensity was likely greater than 
the present study and therefore may have involved a greater recruitment of motor units (i.e. and 
incurring a higher physiological cost) and higher blood flow to the active muscle.  This may explain 
why ‘all out’ HIE sprint ergometer cycling resulted in significant improvements in insulin 
sensitivity in 2-weeks (18,117), compared to the non-significant findings from the current 4-week 
intervention at an intensity of 85-95% HRpeak.  
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Another potential explanation for why six sessions of ‘all out’ cycle ergometer sprints resulted in 
significant improvements in insulin sensitivity, as opposed to the lower intensity exercise protocols 
utilised in the present study, may arise from glucose uptake following exercise. Burgomaster et al. 
(119) previously reported a significant 20% increase in vastus lateralis GLUT4 content following 
two weeks of ‘all out’ repeated cycle ergometer sprints. Enhanced GLUT4 content and subsequent 
improvements in glucose uptake have been reported to improve insulin sensitivity (118). Indeed, 
these changes are likely to be positively correlated with exercise intensity given that glucose 
(mobilised via GLUT4-related pathways) becomes the primary fuel for cellular metabolism when 
exercise transitions from moderate (50-70% HRpeak) to high (> 80% HRpeak) intensity (120). 
With this in mind, the disparate findings for insulin sensitivity between the current study and those 
involving 2-weeks of ‘all out’ cycle ergometer sprints (18,117) may result from the intensity 
prescribed for each interval. From this it could be surmised that for significant improvements in 
insulin sensitivity to occur in 4-weeks or less, the intensity of each HIE interval may need to be ‘all 
out’ (118).  If the intensity of exercise training is lower, then the duration of the training program 
may need to be longer than the present 4-weeks (121,122). 
 
Insulin-like growth factor axis 
It was hypothesised that exercise training would reduce IGF-I and increase in IGFBP-III. Further, 
these changes were expected to be greater in the HIE group compared to the MIE group due to the 
potentially greater improvements in insulin sensitivity that were also expected to occur in the HIE 
group. In contrast to our hypothesis, no significant differences within or between training groups 
were found for IGF-I or IGFBP-III at the end of the 4-week intervention.  
 
A possible explanation for the non-significant findings from our study may be related to a 
‘normalisation’ effect of exercise, whereby plasma IGF-I and IGFBP-III will increase/decrease 
following an exercise intervention depending on whether the baseline measures are below/above 
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normative values. This hypothesis has been briefly suggested by Schmitz et al. (89) to explain non-
significant changes in IGF-I following a 12 month resistance training intervention in breast cancer 
survivors. 
 
In support of this theory, previous trials have reported significant decreases in plasma IGF-I and 
IGFBP-III following 6-months of moderate intensity exercise in breast cancer survivors (123), and 
24-weeks of resistance training in men with prostate cancer treated with androgen deprivation 
therapy (21). The authors of these studies attributed the significant reductions in IGF-I and IGFBP-
III to improvements in body composition, however neither study was appropriately powered to 
conclude this with certainty (21,123). Interestingly, baseline IGF-I and IGFBP-III measures in the 
trials by Santa Mina et al. (21) and Irwin et al. (123) were well above values that have been reported 
in healthy individuals of a comparable age and gender (124), adding support for the hypothesis by 
Schmitz et al. (89) that exercise can shift IGF axis levels into the range reported for healthy persons.  
 
Only one trial has previously investigated the IGF-I and IGFBP-III response to an exercise 
intervention in colorectal cancer survivors; significant increases in IGF-I and IGFBP-III following 
12-weeks of moderate intensity activity were found (110). In this study, pre-intervention values for 
both IGF-I and IGFBP-III were lower than those previously reported by healthy persons of a 
comparable age and gender (124). In line with the changes reported by Santa Mina et al. (21) and 
Irwin et al. (123), this provides further support for the hypothesis that exercise shifts IGF-I and 
IGFBP-III concentrations more in line with normal levels comparable to those in healthy 
individuals.  
 
In the present study, pre-intervention IGF-I and IGFBP-III concentrations were well below what 
has previously been reported in healthy individuals of a comparable age and gender (124). The non-
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significant findings from our study therefore conflict with the mechanism of exercise-mediated IGF 
axis shift postulated by Schmitz et al. (89) and research findings from the trial by Lee et al. (110).  
 
Within the literature, there is currently no consensus on the mechanisms by which exercise mediates 
changes in IGF-I and IGFBP-III (125,126). Further, there is less certainty regarding the direction of 
shift in IGF-I and IGFBP-III following a chronic exercise exposure; increases, decreases and no 
change in the IGF axis have been reported in cancer and non-cancer populations 
(21,22,87,110,123,127). IGF-I and IGFBP-III released via the endocrine system are directly 
mediated via hepatic growth hormone (GH) release (126). Due to financial restrictions, GH was not 
measured in our study, limiting some of the conclusions that can be made to explain why no 
significant changes in IGF-I and IGFBP-III were reported. Despite these limitations, several 
theories to explain the non-significant changes in IGF-I and IGFBP-III in the present study are 
discussed below. 
 
One of the major determinants of IGF-I reductions in response to a physical activity intervention is 
thought to be related to fat loss (128), although there is still some disagreement concerning this 
(125). Participants in the present HIE group had a significant reduction in fat mass over the 4 
weeks, however no relationship between changes in IGF-I, IGFBP-III and any measure of body 
composition over the 4-week intervention was found. This suggests that a potential relationship 
between fat mass and components of the IGF axis is influenced by other factors. 
 
Apart from body composition, mechanisms to explain the relationship between exercise and 
changes in the IGF axis include changes in muscle composition, increased glucose transporter 
protein, increased fatty acid clearance and increased post-receptor insulin signalling (123). 
Although none of these markers were measured in our study, collectively, improvements in these 
measures will generally result in greater insulin sensitivity and lower plasma insulin levels (126). 
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Insulin regulates the hepatic synthesis of IGFBP-1 and IGFBP-2, whereby a decrease in plasma 
insulin will up-regulate the production of IGFBP-I and IGFBP-II. Although IGFBP-III (as 
measured in our study) is the most abundant IGF-I binding protein controlling bioactive IGF-I, 
IGFBP-I and IGFBP-II also play a role in controlling IGF-I bioavailability (13). Up-regulation of 
IGFBP-I and IGFBP-II (via a reduction in plasma insulin) will cause a subsequent down-regulation 
in the hepatic production of IGF-I (13). This cascade happens independent of changes in body 
composition. The non-significant changes in insulin within the present study may therefore explain 
why no significant changes in IGF-I were observed. 
 
Similarly to the discussion surrounding insulin sensitivity, the length of the intervention may 
explain the non-significant changes in the insulin-like growth factor axis found in our study. Indeed, 
our trial was the first to explore changes in these biomarkers via a 4-week physical activity 
intervention within cancer survivors. Previous studies that have reported significant changes in the 
insulin-like growth factor axis in response to a physical activity intervention in cancer survivors 
have been 6-months (123), 24-weeks (21), and 12-weeks (110) in duration.  
 
Apart from systemic (endocrine) production, IGF-I and IGFBP-III are also produced locally via 
paracrine and exocrine mechanisms. Research identifying increased muscular performance 
following an exercise intervention without a concurrent change in endocrine-produced IGF-I has 
concluded that exercise-induced IGF-I changes are likely to be locally produced 
(exocrine/paracrine) (126). IGF-I and IGFBP-III measured via plasma (as in our study) would 
therefore not reflect changes that occur outside of the circulatory system. This may explain why in 
the present study no significant changes in IGF-I or IGFBP-III were reported following the 
intervention.  
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Based on the non-significant findings relating to the IGF axis in the present study trial and the 
subsequent exploration of why our results did not support our initial hypothesis, future trials would 
benefit from to using biochemical techniques that measure both paracrine and exocrine IGF-I and 
IGFBP-III. As discussed by Sax et al. (129), the IGF axis is a plausible mechanism linking physical 
activity to improved survival following colorectal cancer diagnosis. It may however be apparent 
that the IGF components responsible for this association are produced exclusively via 
paracrine/exocrine, rather than by endocrine mechanisms.  
 
Body composition 
It was expected that lean mass would increase significantly in the HIE group in comparison to the 
MIE group due to the potentially greater recruitment of motor units during exercise compared to 
that for the MIE group. Further, it was expected that there would be similar decreases in fat mass 
for both groups; this is consistent with the current position that for weight loss moderate and 
vigorous intensity exercise are equally as effective (130). In the present study, significant 
improvements were reported for lean mass, fat mass, and body fat percentage at the end of the 4-
week intervention for the HIE group only.  
 
For the HIE group only the present findings are in contrast to trials in other cancer survivors, which 
have failed to report improvements in fat mass, lean mass and body fat percentage in response to an 
exercise intervention (110,123). In colorectal cancer survivors, no significant improvements in body 
fat, lean mass, or body fat percentage were reported in response to a 12-week moderate intensity 
aerobic exercise intervention (110). Similarly, however with breast cancer survivors (123), 6 
months of moderate intensity aerobic training did not significantly alter body fat percentage. These 
investigations utilised DEXA to analyse body composition; the same technique used in our trial. 
The reason for the disparity between the current study and previous reports may be due to the 
physiological response to the high intensity interval protocol used in our trial. No other studies 
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utilising the present ‘4x4’ high intensity interval protocol (122,131,132) have included measures of 
body composition (121).  
 
The significant within-group decrease in fat mass reported by the HIE group may be due to a 
number of mechanisms including increased fat oxidation and decreased appetite following exercise. 
Beta-oxidation (133) and lactate production (134) have been found to be 24% and 80% greater, 
respectively, after HIE compared to MIE. Further, catecholamine (135) and growth hormone 
production (136) following acute bouts of HIE have been reported as being higher than levels 
produced after MIE (137). Collectively, these biochemical responses indicate a superior degree of 
fat-oxidation following an acute bout of HIE compared to MIE. In the present study, no significant 
between-group differences were found for fat mass following the intervention, however the 
physiological mechanisms outlined above may, in part, explain the significant reductions in fat 
mass reported for the HIE group only.  
 
The changes in body composition found for the HIE group in the current trial are clinically 
significant. Colorectal cancer survivors have a 1.4 fold increased risk for the development of second 
primary colorectal cancers compared to healthy populations (5).  Epidemiologic data have shown 
that a 10 kg gain in fat mass increases, in a linear fashion, the risk of developing colorectal cancer 
by 33% (138). Participants in the present HIE group decreased their fat mass by 0.8 kg, which 
would reasonably lead to a decrease in relative risk for the development of second primary 
colorectal cancers (138). Although the cohort described by MacInnis et al. (138) did not include 
survivors of colorectal cancer, their findings suggest that as a result of their fat loss, participants in 
the present 4-week study may have decreased their relative risk for the development of second 
primary colorectal cancers by ~3%.   
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The significant increase in lean mass for the HIE group following the 4-week intervention also 
warrants discussion. In previous exercise interventions for colorectal cancer survivors involving 
resistance (139) and aerobic (19) training, no significant changes have been reported in lean mass. 
Despite both these trials being much longer than our trial (12-weeks), the intensity of exercise 
prescribed in the aforementioned interventions was below the intensity utilised in our HIE protocol 
(50-70% HRpeak versus 85-95% HRpeak). This disparity likely underpins the marked 
improvement reported for lean mass in our HIE group. Mechanistically, the significant within group 
increase in lean mass from baseline for those in the HIE group is likely due to the greater degree of 
muscle fibre recruitment compared to MIE training (118). The significant improvements in lean 
mass reported for the HIE group may also underpin the reductions in fat mass via an increase in 
basal metabolic rate (140).  
 
From a clinical perspective, improvements in lean body mass have been inversely correlated with 
mortality risk (141). A one standard deviation increase in lean mass has been associated with a 19% 
and 31% decrease in mortality risk for women and men, respectively (p < 0.001) (141). Beyond 
this, increases in lean mass have been consistently related to improvements in mobility and 
independence, reductions in falls, and decreases in hospital admissions; factors that all contribute to 
quality of life in older individuals (142,143).  
 
To the author’s knowledge, this is the first trial to report significant within-group changes in body 
composition following 4-weeks of HIE in colorectal cancer survivors. Whilst further research is 
required, the current findings support engagement, where possible, of colorectal cancer survivors in 
HIE for beneficial changes in whole body fat and lean tissue mass. Currently, the American College 
of Sports Medicine recommends people engage in 250 minutes per week of MIE in order to achieve 
~1.0 kg loss in fat mass per week (100). In light of this, the significant 0.8kg mean loss in fat mass 
reported for the HIE group following only 114 minutes of exercise per week is clinically 
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meaningful. Future research should utilise the same HIE protocol as the present study to determine 
if these changes are transferrable to other clinical populations.  
 
 
Cardiorespiratory fitness 
It was hypothesised that VO2peak would increase in both training groups following the 
interventions. In support of previous findings from a systematic review of HIE for persons with 
cardiometabolic disease (121), it was further hypothesised that the changes in VO2peak  would be 
significantly greater in the HIE group. Over the 4-week intervention, significant within-group 
improvements were reported for VO2peak in both HIE and MIE groups (23.0% and 1.9%, 
respectively).  
 
The absolute increase in VO2peak of 5.3 mL/kg/min for the HIE group in our study is greater than 
improvements reported previously in colorectal cancer survivors (144). As described by Sellar et al. 
(144), 12-weeks of moderate intensity aerobic and resistance based exercise accounting for a total 
of 18-MET hours per week resulted in a 3.0 mL/kg/min VO2peak improvement. Compared to the 
findings of Sellar et al. (144), the absolute improvement in VO2peak  of 5.3ml/kg/min reported for 
the present HIE group may have been due to the higher exercise intensity employed.  
 
The proposed mechanisms potentially responsible for the significant improvements in VO2peak for 
the HIE group include changes in mitochondrial density (145) and cardiac stroke volume (146). 
Following 6 sessions of ‘all out’ sprinting, healthy males and females (n = 8) significantly increased 
intramuscular citrate synthase (a marker of oxidative potential and mitochondrial function) by 38% 
(p < 0.05) compared to pre-intervention values (145). Further, in a cohort of male university 
students (n = 10), 16 sessions of HIE at an intensity of 90-95% HRpeak significantly improved 
cardiac stroke volume by 13% (p < 0.01) compared to pre-intervention values. Collectively, these 
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physiological changes will result in a greater presentation and utilisation of oxygen at an 
intercellular level which will, in turn increase ones VO2peak (118). 
 
For the present HIE group, the significant within-group improvement in VO2peak may be 
associated with a decreased risk for cancer-specific mortality. A 1-MET increase in 
cardiorespiratory fitness (equivalent to a VO2peak change of 3.5 mL/kg/min) has been equated to a 
5% decreased risk for cancer-specific mortality (147). It is uncertain whether these improvements 
are linear.  However, the present findings for the HIE group suggest a decreased their risk for 
cancer-specific mortality by at least 5% based on their VO2peak improvements. Beyond cancer-
specific health, longitudinal research has identified an inverse association between cardiovascular 
fitness and all-cause mortality in men (148). A 1-MET improvement in VO2peak has been shown to 
be correlated with a 15% reduction in risk for all-cause mortality in a cohort of approximately 
15,000 men (149). In light of these data, participants in the present HIE group may have reduced 
their risk for all-cause mortality by ~ 15% in only 4-weeks.  
 
Our findings support those from a recent systematic review and meta-analysis investigating the 
benefits of HIE for persons with cardiometabolic disease (121). In nine of the ten studies reviewed, 
VO2peak increased by an average of 19.4%; comparable to the 23% reported in the present trial. Of 
these trials, three utilised the same ‘4x4’ training protocol (122,131,132), however the mode of 
intervention was restricted to uphill walking on a treadmill rather than stationary cycling. The 
duration of these trials were 10 (132), 12 (131), and 16 weeks (122), highlighting the novelty of the 
current 4-week intervention. Further, the present data show that significant changes in VO2peak can 
be gained through cycling; an important consideration particularly for persons who are unable to 
walk due to a variety of limitations.  
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Safety and Adherence to Intervention 
The present study is the first to incorporate the ‘4x4’ high intensity exercise protocol in a cancer 
population. Given this, safety, attendance and adherence to the intervention were key areas of 
interest. There were no adverse events in response to exercise reported or observed during the 
intervention; this includes events that occurred outside the training and testing sessions. This is 
consistent with findings from previous research that utilised the same exercise protocol, and found 
no adverse events in person with heart failure (131), metabolic disease (122) and coronary artery 
disease (132). The use of appropriate screening and risk stratification procedures along with 
supervision of each training and testing session by an Accredited Exercise Physiologist in our trial 
is a likely explanation for the absence of adverse events. This was also the case in the trials for 
persons with heart failure (131), metabolic disease (122) and coronary artery disease (132). 
 
Given the higher physiological demands of the HIE compared to MIE training programs, attendance 
rates during HIE training sessions have, in other studies, been slightly lower. In persons with heart 
failure, metabolic disease and coronary artery disease, attendance to training sessions has been 
reported as 92% (131), 90% (122) and 94% (132), respectively. In the present study participant 
attendance was 100%. The disparities in attendance reported between the present study and 
previous studies utilising the same protocol may be due to the length of the intervention. The 
aforementioned interventions were all substantially longer exercise trials, requiring commitments of 
10 (132), 12 (131) and 16 (122) weeks. 
 
An important aspect with regard to the ‘4x4’ high intensity exercise protocol is the reporting of 
adherence to the heart rate zones during the intervals. Participants are required to maintain a heart 
rate between 85% and 95% of their peak during the 4-minute intervals. Presently, no studies 
utilising the ‘4x4’ approach have reported the time taken for participants to actually achieve their 
prescribed heart rate intensity. In the current study, the average time taken to reach the prescribed 
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heart rate intensity in the HIE group was 38-seconds. Anecdotally, the Norwegian Cardiac Exercise 
Research Group (CERG) who developed the ‘4x4’ protocol have advised that heart rate prescription 
should be reached within 2-minutes of the high intensity interval. By comparison, persons in the 
present study were within prescribed heart rate ranges for approximately 68% longer than what is 
recommended by this group.  
 
The safety and adherence outcomes from our trial support the findings from existing research 
utilising HIE interventions in clinical (but not cancer) populations (122,131,132,150). To the 
author’s knowledge, only one other trial has incorporated aerobic HIE at an intensity of 85-95% 
HRpeak in cancer survivors (150). The present findings therefore give weight to the claim that HIE 
is safe, feasible and effective for colorectal cancer survivors, and potentially for other cancer 
survivors.    
 
Limitations and future recommendations 
A key limitation of the present study was the method used to assess insulin sensitivity. The 
euglycemic hyperinsulinemic clamp is currently the most robust measure of insulin sensitivity; 
however this was not utilised in the present study due to cost and participant time requirements. If 
feasible, future investigations with the primary outcome of insulin sensitivity should attempt to use 
this technique over surrogate measures such as fasting glucose, insulin and the HOMA-IR index, 
which were all utilised in the present study. This is of particular importance when participants are 
pre-diabetic or diabetic prior to the intervention; simple indices such fasting glucose, insulin and 
HOMA-IR have been reported to be less precise for these people compared to those with normal 
insulin sensitivity (105,116).  
 
In light of the non-significant changes in the present measures of the IGF axis (despite sound theory 
supporting their mediation via physical activity), future interventions should consider measuring 
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these markers in skeletal muscle. This may allow for the measurement of IGF-I and IGFBP-III 
produced via autocrine and paracrine (rather than endocrine) pathways. If exercise indeed mediates 
the IGF axis through these pathways (as opposed to endocrine), significant changes are more likely 
to be reported following a controlled HIE intervention when using biopsy-based IGF-I and IGFBP-
III measures.  
 
Future studies should also aim to provide a more accurate assessment of total energy expenditure 
outside of the supervised intervention. Indeed, participants from the present study were advised to 
continue their pre-intervention level of activity outside of the intervention until the conclusion of 
the trial. However, an instrumented measure of activity such as accelerometer could be used to 
assess all physical activity performed during the intervention period – activity that could potentially 
influence the outcome measures.  
 
Presently, there is no evidence to support the conclusion that moderate intensity exercise is more 
beneficial than no exercise for the insulin-like growth factor axis in colorectal cancer survivors. 
While the absence of a non-exercising control group in this study may be considered a limitation, 
the MIE group met the current exercise oncology guidelines; comparison of the HIE training 
responses to the MIE training responses involved the MIE essentially assuming a control condition.   
 
It would be useful to include a participant follow-up component in future studies. In the present 
trial, no additional correspondence was made with participants subsequent to their discharge from 
the intervention. It therefor remains unclear as to whether participants continued to engage in HIE 
after the intervention, and as a consequence, preserve the physiological improvements that were 
developed during the study. 
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Finally, one of the key limitations presented by this study was recruitment of suitable participants. I 
was able to recruit 29 participants from the 556 people invited to participate (5%). The inclusion 
criteria in relation to age, was wide to encourage recruitment, which is notoriously difficult in this 
clinical patient group. Therefore, the results of the study should be treated with caution when 
translating them to particular age groups.  
 
Additionally- and unfortunately we weren’t powered to run the sub-analyses by age groups. Larger 
trials would be needed for this to be possible. Future trials targetting specific age groups are 
required to determine the effects of the different types of exercise on younger and older colorectal 
cancer survivors. 
Based on the results from our trial, the following sample sizes would be required to achieve an 80% 
power (two tailed, alpha level of 0.05) in future trials utilising the same population and intervention;  
 
HOMA-IR: effect size = 0.3685771, sample size = 117/group. 
Fasting insulin: effect size = 0.4165356, sample size = 92/group. 
IGF-I: effect size = 0.5471232, sample size = 54/group. 
IGFBP-III: effect size = 0.1943924, sample size = 417/group. 
 
Conclusions 
The present study found no change in markers of insulin sensitivity (apart from 120 min glucose), 
IGF-I or IGFBP-III in response to 4-weeks (12 exercise sessions) of moderate- and high-intensity 
exercise training with colorectal cancer survivors.  This was despite there being significant 
improvements in VO2max and body composition – improvements that are known to be associated 
with decreases in all-cause mortality (including cancer).  
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CHAPTER 4  CONCLUSIONS       
 
While the benefits of physical activity for the prevention of colorectal cancer and reduction in 
disease-specific mortality post-diagnosis are well established, the physiological mechanisms by 
which physical activity can mediate these outcomes remains to be determined. The increased 
incidence of colorectal cancer in persons with diabetes has developed interest in hyperinsulinemia 
as a potential mediating factor for the development of first and second primary cancers. Apart from 
insulin sensitivity, the IGF axis is the most plausible mechanism; there is evidence to suggest that a 
decrease in IGF-I and an increase in IGF-III can reduce disease-specific mortality. In colorectal 
cancer survivors, there is evidence to suggest that physical activity can deliver a positive effect on 
insulin sensitivity and the IGF axis. Given that colorectal cancer survivors are at a heightened risk 
for the development of a second primary colorectal cancer (compared to persons without a previous 
cancer diagnosis), understanding how physical activity can mediate these biological markers is 
crucial.  
 
The current physical activity recommendations for cancer survivors suggest 150 minutes of 
moderate intensity exercise each week (43). There is however developing evidence suggesting that 
high intensity exercise is more beneficial for improvements in cardiorespiratory fitness and insulin 
sensitivity. Prior to the study included in chapter 3 of this thesis, insulin sensitivity and the IGF axis 
were yet to be measured in response to a high intensity exercise protocol in colorectal cancer 
survivors.  
 
The aim of the randomised controlled trial included within chapter 3 of this thesis was thus to 
compare the effect of moderate versus high intensity exercise on insulin sensitivity and the IGF axis 
in colorectal cancer survivors. Although no changes were consistently reported in all measures of 
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insulin sensitivity and the IGF axis, significant improvements were reported in body composition 
for the high intensity exercise group only. Beyond the novelty of these changes in only 4-weeks, 
improvements in fat and lean mass correlate with reductions in cancer-specific and overall 
mortality.  
 
In light of the findings from this thesis, future investigations should continue to investigate the 
effect of HIE on various biomarkers in CRC survivors. Indeed, physical activity has been shown to 
have a protective effect for the development of colorectal cancers, with higher intensity exercise 
being even more beneficial. Identifying the physiological mechanism supporting this association 
will broaden our understanding of the nexus between physical activity and the development of 
colorectal cancers.   
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Abstract 
Physical activity (PA) is related to colorectal cancer (CRC) mortality, with approximately 15% of 
CRC deaths worldwide attributable to physical inactivity. Moreover, higher levels of PA in CRC 
survivors have been associated with a reduced risk of the disease recurring. Despite the 
recognised nexus between PA and the risk of CRC, the physiological mechanisms underlying the 
inverse relationship between PA and mortality following CRC diagnosis are less apparent, with 
evidence primarily drawn from epidemiological studies. The insulin-like growth factor (IGF) axis 
plays a central role in cellular growth, proliferation regulation, differentiation and apoptosis. 
Specifically, high levels of insulin-like growth factor 1 (IGF-1) have been consistently linked to the 
severity of CRC tumours. Further, insulin-like growth factor binding protein 3 (IGFBP-3) regulates 
the bioavailability of IGF-I and therefore plays a central role in CRC prognosis. Decreasing levels 
of IGF-1 and increasing levels of IGFBP-3 may thus be a plausible mechanism underlying the 
inverse association between PA and CRC survival.  
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Introduction 
Of all cancers, colorectal cancer (CRC) has the fourth highest incidence rate worldwide 
and it is estimated that CRC is responsible for the deaths of approximately 608,000 people 
each year (1). Given these statistics, reducing CRC incidence, recurrence and improving 
survival have emerged as major public health priorities.  
 
Physical activity (PA) has been specifically linked to CRC mortality, with approximately 
15% of CRC deaths worldwide being attributable to physical inactivity (151) Further, 
epidemiological data show a significant decrease in disease-specific mortality for 
individuals who are physically active after diagnosis compared to those who are not 
(29,30).  However beyond recognising a relationship between PA and CRC survival, the 
biological mechanisms that underpin this association are not entirely clear. Given that the 
insulin-like growth factor (IGF) axis has been implicated as a key host pathway responsible 
for the association between PA and CRC specific mortality (33-35),  using PA to influence 
the IGF axis may represent an effective means of reducing CRC mortality and improving 
survival. This paper will review the available evidence relating to PA following CRC 
diagnosis, the IGF axis and survival from the disease. 
 
1.0 Physical Activity and Colorectal Cancer  
An inverse relationship between PA and the incidence of CRC has consistently been reported in 
the literature (4,36,37). Furthermore, engaging in PA after CRC diagnosis is associated with 50-
60% reductions in disease-specific mortality (23,38*40). Despite the important role PA has for the 
health of survivors following CRC diagnosis, specific PA guidelines for reducing the risk of CRC-
related mortality following diagnosis do not yet exist.  
 
1.1 Physical Activity and Colorectal Cancer Incidence 
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Over the past ten years, three meta-analyses (4,36,42) have reported an inverse relationship 
between PA and the incidence of colon cancer. Samad et al. (36) analysed nineteen cohort and 
twenty-eight case-control studies and identified a relative risk (RR) for developing colon cancer of 
0.79 when comparing the recreational PA of the most to the least active men. For women, a RR of 
0.71 was identified for recreational PA when comparing the most active to least active (36). More 
recently, Wolin et al. (4) found a RR of 0.76 for both men and women when comparing the most to 
the least physically-active individuals. Further, Boyle et al. (37)  highlighted an inverse dose-
response relationship between PA and colon cancer risk in eleven of the twenty-one studies 
included in their analysis.  
 
Whilst these results offer support for the promotion of PA to reduce the risk of colon cancer, there 
is little evidence that PA can decrease the risk of developing rectal cancer (4,36,42). The reason 
for this disparity is unknown. The closest understanding to the relationship between PA and rectal 
cancer is derived from studies that demarcate the colon into proximal and distal sub-sites during 
statistical analysis. However, findings from these studies offer no significant differences between 
proximal and distal colon regions with a RR of 0.73 and 0.74, respectively, when comparing the 
most to the least physically-active individuals (37). A greater understanding of the physiological 
link between PA and colon cancer from a survival perspective may explain why rectal cancer 
incidence does not appear to be mediated by PA.  
 
1.2 Physical Activity and Colorectal Cancer Survivorship 
Following conventional treatment, CRC survivors who remain or become physically active have a > 
50% reduction in cancer-specific mortality over those who are inactive (38*40). Indeed, 
researchers recommend exercise as an adjuvant to conventional treatment for those diagnosed 
with the disease (4,23,36,38*40,42).  
 
Meyerhardt et al. (38) found an inverse relationship between PA and hazard ratio for CRC-specific 
mortality in male survivors. In a cohort of 661 men, those who engaged in more than 27 metabolic 
equivalent of task (MET) hours of PA per week had a CRC specific mortality hazard ratio of 0.47 
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compared to those who engaged in less than 3 MET-hours per week (38). In a cohort of 573 
female CRC survivors, a RR of 0.39 was found for those who engaged in at least 18 MET-hours of 
PA per week compared to those who engaged in less than 3 MET-hours per week (39). Both 
studies found no change in statistical significance following adjustment for cancer stage (I-III), body 
mass index (BMI) and pre-diagnosis levels of PA. Such evidence highlights the importance of PA 
following diagnosis irrespective of pre-diagnosis activity levels. Although the specific frequency, 
intensity, type and mode of PA required for reductions in CRC specific mortality is uncertain, 
Meyerhardt et al. (38) have indicated that a protective effect for this measure occurs at 
approximately 9 MET-hours per week. This volume of PA aligns well with the current adult PA 
guidelines for health benefits (152).   
 
The majority of studies that have investigated the relationship between PA and CRC survival have 
not reported the frequency, intensity, duration and/or mode of activity of the participants (4,23,36,38*40,42). To a large part, this can be attributed to the limitations of self-report PA 
measures used in these studies, which typically estimate activity levels using MET values. It has 
been shown that participants tend to over-report than under-report PA when recalling previous 
activity levels (46). This limits the conclusions that can be drawn from studies with respect to the 
’dose’ of PA required to elicit a protective effect. Research that involves structured PA 
interventions is required to better understand the relationships between CRC survival and PA that 
have been identified in prospective, case-control studies. Results from these intervention trials will 
help to determine the optimal ‘dose’ of exercise required to reduce CRC incidence and disease-
specific mortality post-diagnosis. The Colon Health and Life-Long Exercise Change trial 
(CHALLENGE) (25) aims to address this limitation; this ongoing randomised controlled trial 
incorporates a multicentre PA intervention utilising instrumented measures of PA and aerobic 
fitness for people with stage II and III colon cancer. The primary outcome of this trial is disease-
free survival, with cardiovascular fitness a secondary endpoint. This study will also track key 
biological markers believed to underpin the relationship between PA and colon cancer risk.  
2.0 Insulin-like Growth Factors and Colorectal Cancer 
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Changes in gastrointestinal transit time, inflammation, immune function, genetic mutations, insulin 
and the IGF axis have all been suggested as mediators to explain the relationship between PA and 
CRC incidence and disease-specific mortality (2,3). Specifically, it is believed that the IGF axis 
plays a central role in cellular growth, proliferation regulation, differentiation and apoptosis (12,13). 
Given these mechanisms, IGFs and their binding proteins (IGFBPs) have been identified as a key 
research focus in CRC pathology (14).  
 
The IGF axis has been linked to the incidence of CRC, along with the risk of tumour metastases 
following diagnosis (35,153). Cross-sectional research has also found associations between the 
IGF axis and the graded severity of CRC carcinomas (14,72,73). Manipulation of the IGF axis 
through PA may therefore be a promising therapy for preventing CRC, as well as reducing the 
likelihood of CRC-specific mortality post-diagnosis. 
 
2.1 Insulin-like Growth Factor Axis  
The IGF axis consists of two polypeptide ligands (IGF-I and IGF-II), two cellular membrane 
receptors (IGF-IR and IGF-IIR), and six binding proteins (IGFBP-1 through IGFBP-6). IGF-I and 
IGF-II are produced via the endocrine, paracrine and autocrine systems (51). Growth hormone 
(GH) plays a dominant role in the upregulation of IGF-I with serum levels peaking around puberty 
and then decreasing throughout life (52,53). IGF-I levels are also influenced by sex and nutritional 
status with higher levels found in females (54), periods of excess energy intake (55) and obesity (52). Unlike IGF-I, the release of IGF-II is GH independent and levels remain stable after puberty (51). At a cellular level, IGF-I and IGF-II accelerate cell cycle progression through the growth 
phase where DNA replication occurs (56). Analogous to this growth-facilitating effect, IGF-I and 
IGF-II have the capacity to block cellular apoptosis. These processes have been reported in 
healthy (16) and malignant tissue (57), highlighting the potential role of IGF-I and IGF-II in the 
progression of CRC following diagnosis. 
 
The biological actions of IGF-I and IGF-II are mediated via two cell-surface receptors; IGF-IR and 
IGF-IIR (16). Because of the structural similarities between IGF-I and IGF-II, the IGF-IR is able to 
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bind both molecules albeit at different affinities. IGF-IR favours IGF-I, binding the molecule at a 2-
15 fold higher affinity than IGF-II (58). Unlike the IGF-IR, the IGF-IIR does not bind IGF-I; this 
receptor specifically binds IGF-II, and at a 500-fold affinity greater than the IGF-IR (13). Because 
binding of IGF-II to the IGF-IIR results in degradation of the molecule, the intra-cellular actions of 
IGF-II are thought to be primarily mediated through the IGF-IR (59). This complex association 
underpins the uncertainty that exists for the role of the IGF axis within the relationship between PA 
and CRC.  
 
The majority (~75%) of IGF-I and IGF-II produced via the endocrine system are bound in a ternary 
complex with IGFBPs and an acid labile subunit (ALS) (63). The remaining IGF-I and IGF-II 
circulates in free form or in a binary unit with IGFBPs only (63).  Because ALS only has an affinity 
for IGF-I/IGF-II that is bound in a IGFBP complex, IGFBPs are thought to control the bioavailability 
of IGF-I and IGF-II (64). This is actioned via three distinct pathways; 1) transportation, 2) 
prolonging the half-life of IGFs and protecting them from degradation, and 3) modulating the 
interaction between IGFs and their receptors (65). When combined in the ternary unit, IGF-I and 
IGF-II are unable to bind to the cell surface receptors, IGF-IR and IGF-IIR. This is due to the up to 
50 fold higher affinity of IGFBPs for IGF-I and IGF-II over their respective receptors (65). The 
outcome of this affinity is thought to be the inhibition of IGF receptor activation, which in turn 
prevents IGF-I and IGF-II mediated cellular proliferation and reduces anti-apoptosis. In contrast, 
IGFBPs prolong the half-life of IGF-I and IGF-II via the prevention of proteolytic degradation that 
would normally occur if IGF-I and IGF-II were circulating in isolation (63). This results in a 
lengthening of IGF-I and IGF-II bioavailability (66). Given these differing processes, IGFBPs can 
facilitate or inhibit the mitogenic actions of IGF-I and IGF-II. These mechanisms indicate that 
IGFBPs may be of equal importance to IGF-I and IGF-II in mediating cellular growth and 
understanding how PA influences CRC incidence and mortality.  
 
In serum, IGFBP-3 is the most abundant IGF binding protein, carrying approximately 90% of all 
bound and free circulating IGF-I and IGF-II (34). Independent to its association with IGF-I and IGF-
II, IGFBP-3 has been found to have a pro-apoptotic and anti-proliferative capacity (67). This has 
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led to a focus on this specific binding protein as a mediator for the development and progression of 
colorectal neoplasms.  
 
A limitation to the measurement of these biomarkers in existing cancer research is that they may 
not reflect downstream cellular growth. Assays used to measure IGF-I and IGF-II do not 
discriminate between free form IGF-I/IGF-II, and that which is bound in binary and ternary units (64). Because of this, current techniques may not reflect the bioactive IGF-I and IGF-II that are 
able to interact with cellular receptors. Furthermore, given that IGFBPs have both growth 
facilitating and inhibiting effects, direct measures of these biomarkers cannot accurately predict 
pro- or anti-proliferative processes. An assay that overcomes these limitations will enhance the 
understanding of how exercise influences the IGF axis interaction with carcinomas. Identifying the 
action of intracellular growth processes rather than merely measuring circulating levels of these 
biomarkers is needed. Nonetheless, reductions in plasma IGF-I and IGF-II, and increases in 
IGFBP-3 suggest a more favourable outcome for the prevention of CRC and reductions in disease-
specific mortality. 
 
2.2 Insulin-like Growth Factors and Colorectal Cancer Survival 
There is strong epidemiological evidence linking IGF-I, IGF-II and IGFBP-3 to the incidence of 
CRC (35,153*157). What is less apparent is the nexus between the IGF axis, tumour metastasis 
and tumour recurrence. Although 5-year relative survival for isolated CRC is promising (89.9%), 
those who experience regional and distant tumour metastasis following diagnosis have a poorer 
prognosis, with expected survival rates of 69.6% and 11.9%, respectively (158).  
 
Research has identified significant associations between tumour severity and IGF-I, IGF-II and 
IGFBP-3 (14,72,73,75,76). These studies have focussed on tumour grade and metastasis, where a 
greater tumour grade and extent of metastasis infers a heightened CRC-specific mortality risk (14,72,73,75,76).  In an animal model, IGF-I has been found to influence colon cancer tumour 
growth and metastasis in liver-IGF-I deficient (LID) mice, which have approximately 75% less 
endogenous IGF-I than controls (76).  Following transplantation of colon adenocarcinomas, LID 
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mice had smaller and fewer tumours with less liver metastases than controls. Further, exogenous 
IGF-I administration in both controls and LID mice increased the rate of tumour progression and 
metastases compared to mice treated with saline (76).  
 
Findings from human in vivo research examining IGF and CRC staging have produced varying 
results (14,72*75). Prospective samples from men and women undergoing a colonoscopy 
identified high-risk adenomas were positively associated with serum IGF-I and inversely 
associated with IGFBP-3 (72). Supporting this, in a cohort of 125 CRC patients, higher serum 
concentrations of IGF-I were found in those with metastases compared to those with localised 
CRC (73). Similar findings for IGF-I and adenoma severity were reported by Jacobs et al. (74). 
IGF-II has also been linked to CRC severity with higher serum levels found in concurrence with 
secondary cancers (14). In contrast to these results, no significant differences in serum IGF-I were 
reported with patients who had moderate adenomas compared to advanced carcinomas (75). 
Nonetheless, the weight of the limited available evidence tends to support a positive relationship 
between IGF-I/IGF-II and CRC specific mortality and an inverse relationship between IGFBP-3 and 
CRC specific mortality.  
 
Given the pathways by which IGF-I and IGF-II stimulate cellular proliferation, the expression of 
IGF-IR and IGF-IIR in colonic carcinomas is likely to influence tumour progression. A high 
presence of these receptors in tissues would allow for enhanced activation of intracellular growth 
processes via IGF signalling. Positive tissue staining for IGF-IR has been more frequently 
identified in primary and high risk CRCs in comparison to non-cancerous adenomas and normal 
tissue (80,81). Further research has identified IGF-IR and IGF-IIR gene expression to be 2.5 and 5 
times higher, respectively, in malignant tissue compared to adjacent non-cancerous tissue (82). 
Despite this finding, the IGF-IIR is not thought to influence tumorigenic potential as it lacks the 
capacity to initiate mitogenic behaviours (59). 
 
In vivo research has examined markers of the IGF axis after CRC diagnosis to determine their 
relationship with disease-specific mortality. Wolpin et al. (78) addressed this among 373 
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participants over 13 years, and found no associations between pre-diagnosis IGF-I and IGFBP-3, 
and mortality in those who developed CRC. Given that lifestyle factors such as diet, obesity and 
PA are known to influence IGFs (52,64), failure to include these confounders into the analysis may 
have contributed to the lack of significant findings with regard to IGF-I and IGFBP-3. Following 
CRC diagnosis, higher circulating IGFBP-3 has been correlated with a greater response to 
chemotherapy, arrested rate of tumour progression, and an increase in overall survival (79).  
 
The varied physiological findings reviewed above highlight the need for robust interventional 
designs to clarify the relationships between IGF-I, IGFBP-3 and CRC mortality. Larger sample 
sizes coupled with improved assays that more precisely measure how IGF-I, IGF-II and IGFBP-3 
influence cellular growth will advance the understanding of these relationships.  In addition, 
confounding factors such as energy intake and PA following CRC diagnosis need to be either 
controlled for or accurately monitored. Notwithstanding these limitations, there is strong evidence 
to support a mechanistic link between IGFs and heightened CRC mortality following diagnosis, 
whereby increased levels of IGFBP-3 and decreased circulating levels of IGF-I and IGF-II are 
associated with reduced disease-specific mortality.  
 
3.0 Physical Activity and the Insulin-like Growth Factor Axis  
The physiological response of IGFs to PA is inconsistent; increases, decreases and no change in 
the IGF axis have been reported in cancer and non-cancer populations (20,21,84,86*89). While the 
reason for this inconsistency is not clear, some researchers believe that negative energy balance 
may underlie the mechanism/s (88), while others purport that it may be more closely related to 
energy flux (86) and physical conditioning (87). Although limited, there is evidence from trials 
involving CRC populations to indicate that changes in these biomarkers driven by PA can have 
favourable outcomes for disease-specific mortality (23).  
 
Only one intervention study has investigated the influence of PA on the IGF axis in a CRC 
population. Following 12 weeks of unsupervised PA of 18 to 27 MET-hours per week, significant 
increases in IGF-I and IGFBP-3 were found (19). Given that the intervention was unsupervised 
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and adherence was measured via a self-reported questionnaire, the precise quantity and intensity 
of PA completed is unknown. Furthermore, prospective evidence demonstrated a one standard 
deviation increase in IGFBP-3 was associated with a 51% reduction in cancer-specific death for 
those who were physically active (24). The same association was not seen for inactive individuals 
or for IGF-1 (24). This indicates that PA is capable of eliciting a beneficial shift in disease-specific 
mortality that is manifested by a measureable biochemical change. Whilst it cannot be concluded 
without further research why the IGF-I response does not reflect that of IGFBP-3, there likely exists 
a delicate interplay between the IGF axis and other exercise-induced biochemical responses.     
 
Although not within the subset of CRC, research in other cancer pathologies has examined the 
relationship between the IGF axis and PA. In a cohort of 26 males diagnosed with prostate cancer 
and currently receiving androgen deprivation therapy, it was found that IGFBP-3 significantly 
increased and IGF-I significantly decreased in men undertaking a six month resistance training 
program (21). No significant changes in these biomarkers were reported for men in the aerobic 
training arm. Although no analysis of this dissonance was mentioned in the paper, it is interesting 
to note the discrepancy with regard to the exercise prescription in both treatment arms. Those in 
the resistance training group were given a set of exercises to complete in the program whereas 
those in aerobic group were encouraged to exercise at 60-80% of their age-predicted maximum 
heart rate via feedback from a wristwatch monitor. No baseline test was completed to confirm this 
heart rate range, therefore the intensity range completed by participants in the aerobic group may 
have been inadequate to elicit changes in the IGF axis that those in the resistance training group 
experienced.  
 
Several studies have measured the response of IGFs to a PA intervention in breast cancer 
survivors. Fairey et al. (84) tracked the changes in IGF-I, IGF-2 and IGFBP-3 following 15 weeks 
of moderate intensity aerobic exercise; significant increases in IGFBP-3 and decreases in IGF-I 
were found, including decreases in their molar ratio, which is thought to reflect bioactive IGF-I.  
More recent research by Irwin et al. (20) tracked breast cancer survivors over a 6 month 
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randomised controlled trial, and found similar results for IGF-I but significant decreases in IGFBP-3 
compared to pre-intervention levels.  
 
Schmitz et al. (22) investigated the role of resistance training on the IGF axis in breast cancer 
survivors. Six months of resistance training resulted in significant reductions in IGF-II however no 
significant changes in IGF-I were reported. Compared to Fairey et al. (84), a higher percentage of 
participants in this study were undergoing chemotherapy, which is known to alter IGF-I levels 
(Bonani, 2001) and therefore may have muted the biochemical response to PA. 
 
In addition to PA, negative energy balance through dietary restriction may lead to a reduction in 
IGF-I (55). Several studies involving healthy populations have attempted to address this by 
employing dietary controls in addition to a PA intervention. Nemet and colleagues (88) found IGF-I 
to only decrease following seven days of aerobic exercise when participants were in a negative 
energy balance (assisted via dietary restriction).  In agreement, Smith et al. (91) found no 
differences in groups who experienced the same negative energy balance through PA or diet 
alone. The volume and intensity of PA required to lower IGF-I is not known and it may be that 
without a negative energy balance, longer interventions at a higher intensity or volume of PA are 
required for significant IGF-I changes to occur. Rarick et al. (86) addressed this idea of energy flux 
which accounts for the absolute level of energy expenditure and intake under conditions of energy 
balance. They found that energy balance and baseline aerobic fitness had no impact on IGF-I or 
IGFBP-3 response. These findings are in contrast to those of Smith et al. (91) and Nemet et al. (88), further confounding the relationship between PA and the IGF axis.  
 
Given that dietary intake influences IGF-I levels, controlling for this variable in the days preceding 
blood sampling is crucial to understanding the precise impact of PA on the IGF axis (55). Many of 
the studies investigating the PA/IGF association have not reported dietary intake control prior to 
testing. Further, assays that only measure total IGF-I in circulation rather than free IGF-I or IGF-IR 
activation have generally been used. This measure does not differentiate between IGF-I that is 
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free/bioactive or bound in binary and ternary units (and therefore unable to interact with cell 
surface receptors).  
 
4.0 Conclusions and Future Directions 
While the benefits of PA for the prevention of CRC and reduction in disease-specific mortality post-
diagnosis are well established, the physiological mechanisms by which PA can mediate these 
outcomes remains to be determined. Of the several biological pathways that have been 
considered, the IGF axis is the most plausible mechanism and has subsequently received the most 
interest. Following diagnosis from CRC, there is evidence to suggest that a decrease in IGF-I and 
an increase in IGFBP-3 can reduce disease-specific mortality. While there is evidence to suggest 
that PA may influence IGF-I and IGFBP-3, intervention studies involving a structured PA regime for 
CRC populations examining changes in the IGF axis are required. Understanding the frequency, 
intensity, duration and mode of exercise that each will potentially influence the IGF axis, reduce the 
incidence of CRC and improve survival is needed to inform the development of specific PA 
guidelines for CRC survivors - guidelines that currently do not exist.  
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  120 
177.0 POEHLMAN0ET,0Rosen0CJ,0COPELAND0KC.0The0influence0of0endurance0training0on0insulin*like0growth0factor*10in0older0individuals.0Metabolism0[Internet].0Elsevier;01994;43:1401–5.0Available0from:0http://www.sciencedirect.com.ezproxy.library.uq.edu.au/science/article/pii/00260495949003530
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Appendix B Review of literature outlining the effects of exercise on insulin sensitivity and the insulin-like growth 
factor axis 
 
 
 
Insulin responses to a chronic high intensity exercise intervention in clinical and non-clinical populations 
 
Reference Cohort Exercise Mode (M) and 
Interval Intensity (I) 
Intervals (INT) and 
Recovery Periods (R) 
Frequency (F) and 
Duration of Intervention 
(D) 
Insulin (I) and Insulin 
Sensitivity Changes (ISI) 
Richards et al. 
2010 (117) 
Sedentary, or 
recreationally active 
males and females 
13 cases 
(Ä=29 y) 
10 controls (nil rx) 
(Ä=24 y) 
M) Cycling 
I) Maximal  
INT) 30 s x 4-7 
R) 240 s  
F) 3 / week 
D) 2 weeks 
ISI) ! 
Insulin sensitivity 
measured via 
hyperinsulinemic 
euglycemic clamp 
improved 4.5 fold 
compared to the control 
group * 
Nybo et al.  
2010 (159) 
Sedentary males 
8 cases 
(Ä=37 y) 
9 controls (mod rx) 
(Ä=31 y)  
M) Running, jogging, 
walking 
I) >95% HRmax 
INT) 120 s x 5 
R) Not measured 
F) 2 / week  
D) 12 weeks 
ISI) ! 
 
Insulin sensitivity 
measured via oral glucose 
tolerance test improved 
by 16% in the high 
intensity group compared 
to baseline * 
Sandvei et al. 
2012 (160) 
Sedentary, or 
recreationally active 
males and females 
11 cases 
M) Running, jogging, 
walking  
I) Maximal 
INT) 30 s x 5-10 
R) 180 s 
F) 3 / week  
D) 8 weeks 
ISI) ! 
 
Insulin sensitivity 
measured via oral glucose 
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(Ä=not reported) 
12 controls (mod rx) 
(Ä=not reported) 
tolerance test improved 
by 6% in the high 
intensity group compared 
to baseline * 
 
Tjonna et al.  
2008 (122) 
Males and females with 
metabolic syndrome  
12 cases  
(Ä=55 y) 
10 controls (mod rx) 
(Ä=52 y) 
M) Running, jogging, 
walking 
I) 75-85% HRmax 
INT) 240 s x4 
R) 180 s 
F) 3 / week  
D) 16 weeks 
ISI) ! 
 
Insulin sensitivity 
measured via 
homeostasis assessment 
model for insulin 
sensitivity improved by 
24% in the high intensity 
group compared to 
baseline * 
 
Harmer et al. 
2007 (161) 
Males and females with 
type 1 diabetes 
8 cases 
(Ä=25 y) 
M) Cycling 
I) Maximal 
INT) 30 s x 4-8 
R) 240 s  
F) 3 / week  
D) 7 weeks 
I) "# 
 
Whyte et al.  
2010 (18) 
Sedentary, overweight or 
obese males 
10 cases 
(Ä=32 y) 
M) Cycling 
I) Maximal 
INT) 30 s x 4-6  
R) 270 s  
F) 3 / week  
D) 2 weeks 
ISI) ! 
 
Insulin sensitivity 
measured via oral glucose 
tolerance test improved 
by 19% compared to 
baseline * 
 
Babraj et al. 
2008 (162)  
Sedentary, or 
recreationally active 
males 
16 cases 
(Ä=21 y) 
M) Cycling 
I) Maximal 
INT) 30 s x 4-6  
R) 240 s 
F) 3 / week  
D) 2 weeks 
ISI) ! 
 
Insulin sensitivity 
measured via oral glucose 
tolerance test improved 
by 23% compared to 
 123 
baseline ** 
 
Little et al. 
2011 (163)  
Males and females with 
type 2 diabetes 
8 cases 
(Ä=63 y) 
M) Cycling 
I) 90% HRmax 
INT) 60 s x 10  
R) 60 s  
F) 3 / week  
D) 2 weeks 
ISI) ! 
 
Insulin sensitivity 
measured via area under 
24-hour glucose curve 
improved by 14% 
compared to baseline * 
 
 
Ä; Mean Age. Rx; Exercise Treatment. * p ≤ 0.05. ** p ≤ 0.001.  
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IGF-I and IGFBP-3 responses to a chronic exercise exposure in non-cancer populations 
Reference Cohort Exercise Mode 
(M) and Intensity 
(I) 
Exercise Duration 
(D) and Frequency 
(F) 
Duration of 
Intervention 
IGF-1 Changes IGFBP3 Changes 
Arikawa et al. 
2010 (164) 
 
Sedentary, but 
otherwise healthy 
women 
166 cases 
(Ä=25  y)  
153 controls 
(Ä=25 y) 
M) Various 
aerobic weight 
bearing activities 
I) 80-85% 
HRmax 
D) 30 mins/session 
F) 5 sessions/week 
16 weeks "# "# 
 
 
Barnard et al. 
2003 (165) 
 
Sedentary males 
at elevated risk of 
prostate cancer 
12 cases 
(Ä=60 y) 
14 controls 
(Ä=55 y) 
M) Walking 
I) 70-85%  
D) 30-60 
mins/session 
F) 4-6 sessions/week 
11 days $ 
Total IGF-1 
decreased 59% 
compared to 
control *  
Not measured 
Chicharro et al. 
2001 (166) 
 
Trained male 
cyclists 
17 cases 
(Ä=17 y) 
M) Cycling 
I) Competition 
Intensity 
D) >3500 km 
(~90 h over 3 weeks 
F) Not measured 
3 weeks ! 
Total IGF-1 
increased 78% 
above baseline 
levels ** 
"# 
Eliakim et al. 
1996 (167) 
 
Recreationally-
active adolescent 
females 
10 cases 
(Ä=16 y) 
6 controls 
(Ä=16 y) 
M) Various 
aerobic activities 
(e.g. running, 
dance, team 
sports) 
I) Not measured 
D) 2 h/session 
F) 5 sessions/week 
5 weeks  $ 
Total IGF-1 
decreased by 14% 
compared to 
control * 
$ 
IGFBP-3 
decreased by 10% 
compared to pre-
intervention and 
15% compared to 
control * 
Eliakim et al. 
1998 (168) 
 
Recreationally-
active adolescent 
males 
10 cases 
M) Various 
aerobic activities 
(e.g. running, 
dance, team 
D) 2 h/session 
F) 5 sessions/week 
5 weeks $ 
Total IGF-1 
decreased by 13% 
compared to 
"# 
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(Ä=16 y) 
6 controls 
(Ä=16 y) 
sports) 
I) Not measured 
baseline and 9% 
compared to 
control * 
Filaire et al. 
2003 (169) 
 
Elite adolescent 
female gymnasts 
7 cases 
(Ä=15 y) 
M) Gymnastics 
training 
I) Not measured 
D) 4.5 h/session 
F) 6 sessions/week 
16 weeks $ 
Total IGF-1 
decreased by 50% 
compared to 
baseline ** 
$ 
IGFBP-3 
decreased by 20% 
compared to pre-
intervention 
levels * 
Hellenius et al. 
1995 (170) 
 
Recreationally-
active healthy 
males 
39 cases 
(Ä=46 y) 
39 controls 
(Ä=47 y) 
M) Various 
aerobic activities 
(e.g. walking, 
jogging)  
I) 60-80% 
HRmax 
D) 30-45 
mins/session 
F) 2-3 sessions/week 
6 months  "# Not measured  
Koziris et al. 
1999 (171) 
 
Trained male and 
female swimmers 
14 cases divided 
into 3 teams 
(Ä=18-22 y) 
M) Swimming 
training 
I) Not measured 
D) NR 
F) 5-6 sessions/week 
 
 
5 months !  
Total IGF-1 
increased by 76% 
*, 68% *, no 
significant 
change for third 
team 
! 
IGFBP-3 
increased by 30%, 
97% and 53% 
compared to 
baseline *  
Manetta et al. 
2003 (172) 
 
Trained male 
cyclists & 
sedentary controls 
8 cases 
(Ä=24 y) 
8 controls 
(Ä=25 y) 
M) Competitive 
Cycling 
I) Month 1: 
HR=120-160 bpm 
Months 2-4: 
HR >170 bpm 
 
D) Not measured 
F) 6 sessions/week 
(~17 h total/week) 
4 months  ! 
Total IGF-1 of 
cyclists post 
training higher 
than controls * 
! 
IGFBP-3 
increased by 20% 
compared to 
baseline values *  
 
IGFBP-3 post 
training higher 
than controls *  
Nindl et al. 
2010 (173) 
Healthy females 
13 cases 
M) Endurance 
and interval 
D) 20-30 
mins/session 
8 weeks  "# "# 
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 (Ä=20 y) 
20 controls  
(Ä=20 y) 
jogging 
I) 70-85% 
HRmax  
F) 3 sessions/week 
Nindle et al. 
2004 (174) 
 
Male and female 
dialysis patients 
with end stage 
renal disease 
10 cases 
(Ä=43 y) 
M) Resistance 
exercise 
I) 10-15 reps, 2-3 
sets  
D) 9 
exercises/session 
F) 2 sessions/week 
 
 
12 weeks  $ 
Total IGF-1 
decreased by 15% 
compared to 
baseline * 
"# 
Nishida et al. 
2010 (175) 
 
Sedentary, but 
otherwise healthy 
males 
14 cases 
(Ä=23 y) 
M) Cycling  
I) ~50% VO2max  
D) 60 mins/session 
F) 5 sessions/week 
6 weeks  $ 
Total IGF-1 
decreased by 9% 
compared to 
baseline * 
"# 
 
 
Ounis et al. 
2010 (176) 
 
Sedentary, obese 
girls and boys 
14 cases 
(M=13 y) 
14 controls  
(Ä=13 y) 
M) Various 
aerobic activities 
(e.g. running, 
jumping, balloon 
games) 
I) Not measured 
D) 90 mins/session 
F) 4 sessions/week 
8 weeks  $ 
Total IGF-1 
decreased 17% 
compared to 
baselines and 
22% compared to 
control ** 
$ 
IGFBP-3 
decreased 10% 
compared to 
baseline and 14% 
compared to 
control ** 
Poehlman et al. 
1994 (177) 
 
Sedentary, but 
otherwise healthy 
males and females 
18 cases 
(Ä=66 y) 
M) Cycling  
I) 60-75% 
HRmax  
D) 150-300 
kcal/session 
F) 3 sessions/week  
8 weeks  ! 
Total IGF-1 
increased by 14% 
compared to 
baseline * 
"# 
 
 
 127 
Rosendal et al. 
2002 (87) 
 
Trained healthy 
males and 
untrained healthy 
controls 
12 cases 
(Ä=20 y) 
7 controls 
(Ä=20 y) 
M) Military style 
training 
I) Not measured 
D) 2-4 h/session 
F) 7 sessions/week 
11 weeks $ 
Total IGF-1 
decreased in 
untrained group 
by 15% compared 
to baseline * 
 
Total IGF-1 
decreased in the 
trained group by 
9% at week 4 
compared to 
baseline *, but 
returned to 
baseline at 11 
weeks  
"# 
Schmitz et al.  
2002 (22) 
 
Recreationally-
active healthy 
females 
27 cases 
(Ä=41 y) 
27 controls 
(Ä=42 y) 
M) Resistance 
exercise 
I) 8-10 reps @ 3 
sets 
D) 9 exercises (~50 
mins)/session 
F) 2 sessions/week 
15 weeks  $ 
Total IGF-1 
decreased by 14% 
compared to 
baseline and 24% 
compared to 
control * 
"# 
 
 
 
 
 
 
 
Ä; Mean Age. Rx; Exercise Treatment. * p ≤ 0.05. ** p ≤ 0.001.  
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Appendix C Letter of invitation from phase 1 of recruitment 
<Date>'''«Title»'«Given_names»'«Surname»'«Current_Address»'«Current_Locality»''' Dear'«Title»'«Surname»''Thank'you'for'your'participation' in'The'Cancer'Council'Queensland’s'Colorectal)Cancer)and)
Quality)of)Life'study.'This'research'project'has'provided'us'with'a'wealth'of' information'on'the'health'and'wellFbeing'of'colorectal'cancer'survivors'over'time'with'over'20'publications'to' date' in' national' and' international' scientific' journals.' ' The' research' has' significantly'improved'our'understanding'of'the'issues'faced'by'many'colorectal'cancer'patients'and'it'will'contribute'to'the'ongoing'development'of'better'services'and'support.''''We' are' contacting' you' at' this' time' to' invite' you' to' participate' in' a' new' project' being'conducted'by' the'University'of'Queensland' in'conjunction'with'Cancer'Council'Queensland.'The'study'is'examining'the'health'benefits'of'different'types'of'exercise'for'people'who'have'had'colorectal'cancer.''The'project'is'being'conducted'by'qualified'exercise'physiologists.'''Please' find' enclosed' a' flyer' which' provides' information' on' the' study' and' what' your'participation'would'involve.'''
If you are interested in taking part in this exciting new study, or if you would like more 
information, please contact Andrew Sax, the study coordinator and Principal Investigator, 
at the University of Queensland. 
 
Andrew’s contact details are: Telephone:  0456 746 938.    
Email:   a.sax@uq.edu.au 
 
Thank you once again for' your' time' and' help' with' improving' our' understanding' of' the'impact'of'colorectal'cancer.''Yours'sincerely'
 
 
 
 
 '
Professor'Joanne'Aitken'' ' ' ' ' 'Head'of'Research'Cancer'Council'Queensland'
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Appendix D Recruitment flyer 
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Appendix E Invitation letter to doctors from phase 2 of recruitment 
< Doctors Name > 
< Doctors Address > 
<    >    
< Date > 
 
Dear «LU_Doctors_Title» <                    >, 
 
As you know, the Queensland Cancer Registry collects information on all cases of cancer diagnosed in 
Queensland, as required under the Public Health Act 2005.  One of the most important roles of the Cancer 
Registry is to facilitate research into cancer.  
 
Two studies titled ‘The impact of high intensity interval training on insulin sensitivity in colorectal cancer 
survivors’ and ‘The optimal exercise mode and intensity for colorectal cancer survivors’ health’ are being 
conducted by the University of Queensland in collaboration with the Cancer Council Queensland to 
collectively determine 
  
1. the most effective intensity and type of exercise for colorectal cancer survivors to inform the 
development of guidelines; 
2. whether high intensity (exercise) training results in greater improvements compared to 
moderate intensity training in colorectal cancer survivors; 
3. the effect of dosage, tapering and detraining on the maintenance of these improvements 
following exercise training in colorectal cancer survivors; and 
4. the effect of exercise training on cancer related fatigue in colorectal cancer survivors. 
 
I am writing to seek your permission to approach your patient(s) who is/are registered with the 
Queensland Cancer Registry as having been diagnosed with colorectal cancer. These studies have 
received ethics approval from the University of Queensland Human Research Ethics Committee.  These 
studies have been considered and approved under Part 4 ‘Research’ of the Public Health Act 2005 to use 
the information in the Registry. Following your written approval, the Queensland Cancer Registry would 
send your patient(s) a personal letter signed by you (letter is enclosed for your signature) and an 
information flyer about the studies. Should your patient(s) wish to participate they are asked to contact the 
researchers directly to discuss the studies in more detail. 
 
If you agree to your patient(s) being invited to participate in either of these studies, I would be grateful if 
you would: 
• Complete the enclosed consent form  
• Sign the letter to your patient(s) (the Queensland Cancer Registry requires that this letter to your 
patient(s) is signed by you). 
• Return to us in the reply paid envelope 
 - the consent form and  
  - the signed letter.  
 
If you do not wish your patient(s) to be approached, please indicate on the enclosed consent form and 
return this to us in the reply paid envelope. 
 
It is important for the scientific validity of the research to include responses from as many patients as 
possible.  I greatly appreciate your assistance in this regard.  I would be pleased to discuss any queries 
you may have about this request on (07) 3634 5333. 
 
With thanks,  
Yours sincerely 
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Appendix F  Doctor information sheet 
 
 
The impact of high intensity interval training on insulin sensitivity in 
colorectal cancer survivors 
 
and 
 
Optimal exercise mode and intensity for colorectal cancer survivors’ 
health 
    
 
Introduction       
Colorectal cancer is second only to lung cancer as the leading cause of cancer death in Australia, 
with age, family history, diet, inactivity and smoking identified as being significant risk factors for 
the disease. Research has found that Colorectal Cancer (CRC) survivors with Type 2 Diabetes 
have heightened disease specific and overall mortality rates compared to survivors without this 
associated condition. Moderate intensity physical activity has been found to result in significant 
improvements in insulin sensitivity in this population. High intensity exercise has, in recent years, 
attracted the attention of researchers involved in the management and prevention of a number of 
chronic diseases and improvements in insulin sensitivity have been shown to result from as little as 
two weeks of high intensity training. Whilst these results are promising for the prognosis of Type 2 
Diabetes, the benefits from high intensity exercise are yet to be investigated in colorectal cancer 
survivors.  
 
Further, research indicates that colorectal cancer survivors experience elevated levels of fatigue 
following diagnosis and treatment. Whilst physical activity interventions in this population have 
been found to significantly lower levels of cancer related fatigue, little is known about the influence 
of high intensity training on this measure.  
 
These randomised clinical trials will examine the dose-response effects of physical activity and 
exercise on insulin sensitivity, other identified biological markers associated with colorectal cancer 
risk, and cancer related fatigue. Thus, these studies have the potential to improve our 
understanding of how disease mortality risk can be reduced, particularly for those at risk of Type 2 
Diabetes.   
 
What are the expected outcomes from these projects? 
These studies will enable us to: 
1. Determine the most effective intensity and type of exercise for CRC survivors to inform the 
development of guidelines aiming to reduce the risk of cancer recurrence and improve the 
overall health of CRC survivors; 
2. Determine whether high intensity (exercise) training results in greater improvements 
compared to moderate intensity training in CRC survivors; 
3. Determine the effect of dosage, tapering and detraining on the maintenance of these 
improvements following exercise training in CRC survivors; and 
4. Determine the effect of exercise training on cancer related fatigue in CRC survivors. 
 
 
Study 1: The impact of high intensity interval training on insulin sensitivity in colorectal 
cancer survivors 
 
How could your patients help? 
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If your patient consents to take part in this study, they will be randomly assigned to one of three 
groups: (1) high intensity aerobic interval training – continued, (2) high intensity aerobic interval 
training – tapered, (3) moderate intensity aerobic continuous training. Groups (1) and (3) will 
exercise three times per week for 8 weeks, whereas group (2) will exercise three times per week 
for weeks 1-4, then one time per week for weeks 5-8. Following the 8-week intervention, 
participants will be re-assessed after 4 weeks of no training (week 12).  
 
All exercise sessions will be undertaken at the School of Human Movement Studies on The 
University of Queensland’s St Lucia campus.  
 
What will testing involve? 
Patients(will(be(assessed(at(baseline,(4(weeks,(8(weeks(and(12(weeks(following(the(start(of(training.(We(will(
measure(your(patient’s(body(composition,(and(cardiorespiratory(fitness,(as(well(as(conduct(a(blood(analysis.(
Your(patient(will(also(be(asked(to(complete(a(selfAadministered(questionnaire(to(collect(information(about(
their(quality(of(life,(fatigue(and(dietary(habits.((!
  
(
Study&2:& Optimal&exercise&mode&and&intensity&for&colorectal&cancer&survivors’&health&
 
How could your patients help? 
If your patient consents to participate in this study they will be required to perform three types of 
singular exercise sessions: (1) high intensity interval exercise session, (2) moderate intensity 
exercise session and (3) circuit weight training. The aim of this study is to understand the acute 
response of insulin sensitivity and other biological markers associated with CRC to a single 
session of exercise. This will help determine the optimal exercise mode and intensity to induce 
favourable biological changes to improve the health of colorectal cancer survivors.  
 
What will testing involve? 
Patients will undergo baseline testing consisting of body composition, and cardiorespiratory fitness, 
as well as a blood analysis. Patients will then undergo three exercise testing sessions with blood 
analysis being performed prior to and following exercise to map the duration of exercise-induced 
improvements in biological markers associated with CRC.  
(
 
Who(is(eligible(to(participate(in(these(studies?(
We require men and women who have been diagnosed with Colorectal Cancer. Participants must 
not have any musculoskeletal, neurological, respiratory, or cardiovascular conditions that prevent 
them from safely completing the exercise demands of the study. Participants will also be excluded 
if they are receiving pharmacological treatment to increase their insulin sensitivity and/or 
exogenous insulin therapy.  
 
Are there any risks for my patient? 
Your patient will be exposed to a dual energy x-ray absorptiometry (DXA) to determine body 
composition and bone mass. The amount of radiation is very small and the corresponding risk from 
participating in this study is extremely low.  Patients may experience some initial muscle soreness 
as the result from testing and training. Patients will also be exposed to the normal discomfort and 
risks associated with the blood drawing procedures.  
Will my patient’s information remain confidential? 
All information collected in the study will be used for medical research purposes only. No 
identifiable information that your patient provides will be passed on to any other person who is not 
directly involved in the research. Results will be presented to the scientific community and to the 
public in ways that protect the identity of participants.  
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The conduct of this research involves access to your patient’s identified personal information. The 
information collected is completely confidential and will not be disclosed to third parties without 
their consent, except to meet government, legal or other regulatory authority requirements. A de-
identified copy of this data may be used for other research purposes. However, your patient’s 
anonymity will at all times be safeguarded. This study has been cleared by one of the human 
ethics committees of the University of Queensland in accordance with the National Health and 
Medical Research Council's guidelines. If you would like to speak to an officer of the University not 
involved in the study, you may contact the Ethics Officer on 3365 3924.  
 
Your patient’s participation in this project is entirely voluntary and has no bearing on his or her 
medical care. If you would like further information at any other time, please contact me on 3634 
5333. 
 
Yours sincerely 
 
 
 
Ms Carly Scott 
Registrar, Queensland Cancer Registry 
 
Research Team  
Andrew Sax, BExSS (ClinExPhys) (Hons1) PhD Candidate, School of Human Movement Studies, 
Accredited Exercise Physiologist, University of 
Queensland 
James Devin, BExSS  (ClinExPhys) (Hons1) PhD Candidate, School of Human Movement Studies, 
Accredited Exercise Physiologist, University of 
Queensland 
Gareth Hughes, BExSS  (ClinExPhys) (Hons1) MPhil Candidate, School of Human Movement Studies, 
Accredited Exercise Physiologist, University of 
Queensland 
Kate Bolam, BScApp (Hons)           PhD Candidate, School of Human Movement Studies, 
University of Queensland 
A/Prof David Jenkins, PhD, MSc, BA Lecturer, School of Human Movement Studies, 
University of Queensland 
Dr Tina Skinner, PhD, BScApp (Hons) Lecturer, School of Human Movement Studies, 
University of Queensland 
Prof Suzanne Chambers, PhD Australian Research Council Future Fellow, Griffith 
University 
Prof Joanne Aitken Head of Research and Director Cancer Registries, 
Cancer Council Queensland 
Prof Jeff Dunn CEO, Cancer Council Queensland 
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Appendix G Participant information sheet 
 
The impact of high intensity interval training on insulin sensitivity in 
colorectal cancer survivors. 
 
Principal Investigator:   
Andrew Sax, BExSS (Hons)  PhD Candidate, School of Human Movement 
Studies, Accredited Exercise Physiologist, 
University of Queensland 
E-mail: a.sax@uq.edu.au    
Phone: 0456 746 938  
Co-Investigators:  
Kate Bolam, BScApp (Hons)           
 
PhD Candidate, School of Human Movement 
Studies, University of Queensland 
A/Prof David Jenkins, PhD, MSc, BA Lecturer, School of Human Movement Studies, 
University of Queensland  
Dr Tina Skinner, PhD, BScApp (Hons) Lecturer, School of Human Movement Studies, 
University of Queensland 
Prof Suzanne Chambers, PhD Australian Research Council Future Fellow, 
Griffith University 
Prof Joanne Aitken Head of Research and Director Cancer 
Registries, Cancer Council Queensland 
Prof Jeff Dunn CEO, Cancer Council Queensland 
 
     
Why are we conducting this study? 
Research has found that Colorectal Cancer survivors with Type 2 Diabetes have heightened 
disease specific and overall mortality rates compared to survivors without this associated 
condition. Moderate intensity physical activity has been found to result in significant improvements 
in insulin sensitivity in this population. High intensity exercise has, in recent years, attracted the 
attention of researchers involved in the management and prevention of a number of chronic 
diseases and improvements in insulin sensitivity have been shown to result from as little as two 
weeks of high intensity training. The benefits from high intensity exercise are yet to be investigated 
in colorectal cancer survivors. Further, research indicates that colorectal cancer survivors 
experience elevated levels of fatigue following diagnosis and treatment. Whilst physical activity 
interventions in this population have been found to significantly lower levels of cancer related 
fatigue, little is known about the influence of high intensity training on this measure.  
 
Are(you(eligible(to(participate(in(this(study?(
We require participants who have been diagnosed with Colorectal Cancer.  
Participants must not have any musculoskeletal, neurological, respiratory, or cardiovascular 
conditions that prevent them from safely completing the exercise demands of the study. 
Participants will also be excluded if they are receiving pharmacological treatment to increase their 
insulin sensitivity and/or exogenous insulin therapy. In addition, participants will need to obtain 
consent from their doctor (GP) before participating in the study. 
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What does the exercise program involve? 
Participants will be randomly assigned to one of three groups: (1) high intensity aerobic interval 
training – continued, (2) high intensity aerobic interval training – tapered, (3) moderate intensity 
aerobic continuous training. Groups (1) and (3) will exercise three times per week for 8 weeks, 
whereas group (2) will exercise three times per week for weeks 1-4, then one time per week for 
weeks 5-8. Following the 8-week intervention, participants will be re-assessed after 4 weeks of no 
training (week 12). All sessions will be completed on stationary bicycles. 
 
High intensity groups will exercise at 90% of their maximum capacity for 4x4minute intervals, 
interspersed by 3 min periods of recovery at a lower intensity. Moderate intensity groups will 
exercise at 70% of their maximum capacity for the duration of the session (50 minutes). All 
exercise sessions will include a 10min warm-up and 5min cool-down. With warm-ups and cool-
downs, each exercise session will last approximately 60 minutes in total.  
 
All exercise sessions will be undertaken at the School of Human Movement Studies on The 
University of Queensland’s St Lucia campus. All sessions will be conducted in small groups of 3-4 
participants under direct supervision of a qualified exercise physiologist.  
 
The type of exercise training used in this study has been previously investigated in clinical 
populations including patients with heart failure and type 2 diabetes. No adverse events were 
reported in these trials; high intensity exercise training is safe to use in this population. Blood 
pressure, heart rate and perceived exertion will be monitored during exercise testing and training 
sessions to further ensure the safety of all participants. 
 
What will testing involve? 
Assessments at baseline (i.e., before the training starts), then again 4 weeks, 8 weeks and 12 
weeks following the start of training will include all the measures listed below. All testing will be 
completed by an accredited exercise physiologist trained to conduct each measure. Testing 
sessions take approximately 3 hours to complete and you will need to be 12-hours fasted prior to 
each session (water is fine).  
 
Body composition 
• Height and body weight.   
 
• Muscle and fat mass of the whole body will be measured by dual energy x-ray absorptiometry 
(DXA), a routine technique for the measurement of body composition.  You will lie on a 
specially designed table (as shown in the adjacent photo) for approximately 7 minutes and a 
scanning arm will move above your entire body.  
 
There is no pain or discomfort associated with these measures. 
&
Cardiorespiratory,(aerobic),fitness,,
• Aerobic fitness will be measured via a maximal cardiorespiratory fitness test. The test will 
involve cycling on an exercise bike for 10-15 minutes whilst you breathe through an apparatus 
that measures your oxygen consumption (as shown in the adjacent photo).  
 
 
Blood Analysis: glucose, insulin and other biomarkers of colorectal cancer growth 
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• Blood will be sampled for us to assess insulin sensitivity and other markers that have been 
linked to Colorectal Cancer growth. All blood will be sampled and be analysed at The 
University of Queensland’s School of Human Movement Studies biochemistry laboratory by a 
qualified phlebotomist. You will be required to avoid food and drink (except water) for twelve 
hours before those sessions where your blood will be sampled. On the day of testing, you will 
be required to consume a 75g glucose drink in order to assess your insulin sensitivity. This will 
be followed by 4 blood samples over the subsequent 2 hours. Following blood sampling, you 
will be given an energy snack to minimise the impact of fasting on your exercise 
training/testing.  
 
Questionnaires,,
• Your health history and other general information will be assessed using questionnaires that 
you can complete at home. Quality of life and cancer related fatigue will be assessed by 
questionnaires that can be completed at home. Levels of self-reported physical activity will be 
assessed by the leisure score index from the Godin Leisure-Time Exercise Questionnaire that you 
can complete at home. Dietary information will be collected using a 3-day food diary. 
 
Will I need to provide any medical information? 
We would also like your permission to access important medical information about you throughout 
the study period. In particular, we would like your permission to access your medical and Cancer 
Registry records for research purposes only in order to obtain important medical information about 
your colorectal cancer diagnosis.  
 
Are there any risks associated with being involved in this study? 
DXA uses very low energy x-rays to determine body composition and bone mass. The total dose 
associated with the scans you will undergo in this study is approximately 12 µSv.  In comparison, 
an individual receives approximately 7 µSv for daily natural background exposure, 80 µSv for a 
return trans-Pacific flight, 100 µSv for a chest x-ray, and 2000 µSv for a lumbar spine x-ray.  
Therefore, although radiation is used in the scan, the amount of radiation is very small and the 
corresponding risk from participating in this study is extremely low.   
It is possible that some initial muscle soreness may result from testing and training; however, all 
participants will undertake a warm-up prior to, and cool-down immediately following each session. 
In the event that an emergency occurs, medical assistance will be available from the university 
health service according to our established emergency procedures. 
Lastly, the discomfort associated with the blood drawing procedures is minimal. There is a risk that 
bruising and infection may occur and that the arm might become sore.  Risk of bruising or infection 
from the blood draws will be minimized because all blood will be sampled by a trained 
phlebotomist. The total amount of blood drawn during each testing session will not exceed 12 ml 
which is equivalent to approximately 2 teaspoons. No syringes, lancets, needles or other devices 
capable of transmitting infection from one person to another shall be reused.  All of these items, 
which are disposable, will be destroyed after each use. As an additional safeguard in preventing 
contamination, new disposable gloves will be worn for all blood draws. All contaminated items will 
be disposed of promptly in sharps containers. 
 
All information will be strictly confidential and kept safely locked in a filing cabinet in the principal 
investigator’s office. Should publications result from this study, no reference will be made to any 
individuals.  There is no financial reimbursement for participating in this study.  
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On completion of the intervention and measurements, a summary of study findings and individual 
results will be made available to all participants.  
 
 
PARTICIPATION IS VOLUNTARY AND SUBJECTS ARE FREE TO WITHDRAW FROM THIS 
STUDY AT ANY TIME, FOR ANY REASON. 
 
This study has been cleared by one of the human ethics committees of the University of 
Queensland in accordance with the National Health and Medical Research Council's guidelines. 
You are of course free to discuss your participation in this study with project staff (Andrew Sax 
contactable on 0430 060 872). If you would like to speak to an officer of the University not 
involved in the study, you may contact the Ethics Officer on 3365 3924.  
 
 
 
Thank you for your interest in this study. 
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Appendix H Invitation letter to participant from doctor 
< Patient Name > 
< Patient Address > 
<    > 
    
< Date > 
 
Dear < Patient Title and Name >, 
 
The Queensland Cancer Registry has contacted me about a series of research projects that are 
being conducted by researchers at the University of Queensland in collaboration with the Cancer 
Council Queensland, to help determine the impact of exercise training on the health, wellbeing, 
cancer related fatigue and other factors in colorectal cancer survivors. Information collected during 
the studies will: 
 
! Inform the development of exercise-specific guidelines that may reduce the risks of 
colorectal cancer recurrence in survivors of the disease  
! Specifically assess the influence of exercise intensity and type on biological factors that 
have been associated with the risks of colorectal cancer and also evaluate the relationship 
between exercise intensity and psychological stress among colorectal cancer survivors. 
 
The Queensland Cancer Registry collects, by law, information on all cases of cancer diagnosed or 
treated in Queensland.  All information in the Registry is kept strictly confidential and is held under 
tight security.  
 
There are currently two studies being conducted: 
 
! The effect of a single exercise session on the health of colorectal cancer survivors 
! The impact of 8 weeks of exercise training on the health of colorectal cancer survivors 
 
One of the most important roles of the Registry is to assist cancer research.  These studies have 
been approved under the Public Health Act 2005 to use the information in the Registry.  With your 
consent, the researchers undertaking these studies would like to invite you to participate in this 
research. Would you be willing to take part in these research projects?  
 
Please find enclosed an information flyer that explains a little more about the studies.  If you are 
willing to take part, please contact the project coordinator at the University of Queensland whose 
contact details are included in the information flyer. The project coordinator will provide you with 
more information about the study and determine your eligibility to participate.  
 
Participation in this research is entirely voluntary and any information you provide will be treated as 
strictly confidential.   
 
If you have any questions please call a registry staff member on (07) 3634 5333. 
 
Thank you for your assistance. 
 
 
Yours sincerely 
 
 
 
< Doctors Name > 
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Appendix I  Food Diary 
 
" Please try to replicate your dietary intake from your baseline testing as accurately as 
possible (attached) 
" If you cannot exactly replicate a single meal or day for any reason, please record the 
alternative dietary intake in the corresponding box 
DECLARATION 
I declare that I have tried to replicate my 
baseline dietary intake to the best of my 
ability, except in the circumstances that 
have been outlined below. 
Signature:  -
________________________   Date: -
_______________ 
 
3 DAY FOOD DIARY 
*Please provide as much detail as possible and include all drinks (excluding water). 
*Keep in mind you will be required to follow this diet at 3 other time points during study. 
Day Brkfst Snack Lunch Snack Dinner Snack 
Eg. -Toast with 
honey (2 
slices). 
-Fruit juice 
(1 glass). 
-Chocolate 
biscuit (2 
units). 
-Coffee 
with milk.  
-1 banana. 
-1 Meat 
pie with 
tomato 
sauce. 
-Can of 
coke 
(350mL).  
N/A -Lasagne 
(medium 
portion). 
-Caesar 
salad (half 
plate). 
 
-Skim milk 
(1 glass). 
-Cadbury 
chocolate 
(10 
squares).  
-1 apple. 
1  
 
 
 
 
 
 
     
2  
 
 
 
 
 
 
     
3  
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Appendix J  Godin leisure time physical activity index 
 
